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Chapter 1: Introduction 
Clinical trials are research studies that involve people and test new methods of screening, 
prevention, diagnosis, or treatment of health conditions and diseases.1  Clinical trials may benefit 
individual volunteers by providing access to new treatments before they are available to the 
public and serve the general population by evaluating the safety and efficacy of medical 
treatments; potentially leading to improved treatment options in the future.2  With regard to 
cancer, clinical trials can be categorized by site (breast), type (treatment vs. prevention), phase 
(see Table 1), and stage (degree to which cancer has spread).  The decision-making process and 
barriers to enrollment may differ by phase. For example, phase 1 patients are often sicker and 
have fewer treatment options,3,4 whereas patients considering phase 3 trials often have standard 
treatment alternatives. It should be noted that before medications and therapies are tested in 
humans, they are first evaluated in animal models and laboratory research.  
      
Table 1: Phases of cancer clinical trials1,5 
Phases Purpose # Patients  
Phase 1 Evaluate safety, dose range, side effects, and 
method of delivery (e.g., mouth or vein). 
~ 15 to 80 
Phase 2 Test effectiveness and further evaluate safety.  Usually <100, but up to 300 
Phase 3 Compare effectiveness of a new intervention, or 
new use of an existing intervention, with the 
current standard of care. 
Hundreds or thousands 
Phase 4 Evaluate a drug or treatment after it has been 
FDA approved and marketed to the general 
public (e.g., side effects associated with long-
term use and potential differential effects on 
various populations).  




Lack of insurance coverage for routine patient care costs is one of the many barriers to 
enrollment for patients who might otherwise take part in a clinical trial. With regard to healthcare 
policy for cancer clinical trials, approximately 35 states have passed legislation or instituted 
special agreements requiring health plans to pay the cost of routine medical care received by a 
participant in a clinical trial.6  Additionally, there are provisions in the new Patient Protection 
and Affordable Care Act related to clinical trials.  Beginning in 2014, the act will require health 
insurers to pay for routine costs of care in approved clinical trials for cancer and other life-
threatening diseases. The types of clinical trials that may be covered include treatment, 
prevention, and early detection trials.7 As the general public learns about these insurance 
provisions, more patients may seek out information and participate in clinical trials.  For 
example, a study conducted by Comis et al. found that 8 in 10 cancer patients were unaware that 
clinical trials could have been an option during their diagnosis and treatment period. Yet of those 
unaware patients, 76% reported that they would have been somewhat or very receptive to 
participate.8 
Minority Participation in Clinical Trials: A Complex Issue 
In addition to barriers to enrollment that affect the entire population, several studies have 
shown racial and ethnic disparities in barriers to enrollment. One barrier is, quite simply, that 
minority groups are often unaware of clinical trials.9-12  For example, two studies using data from 
the National Cancer Institute’s Health Information National Trends Survey (HINTS) 
demonstrated that a significantly smaller proportion of black respondents had heard of clinical 
trials compared with white respondents.11,12 In addition, black respondents reported fewer 
positive feelings about sharing their medical data than white respondents.12 In another study 




University of California at Davis Comprehensive Cancer Center, 78% of African-American 
breast cancer survivors reported that their doctors did not talk to them about clinical trials, yet 
the same percentage said they would have enrolled if eligible.13  
The literature regarding minority willingness to participate in clinical trials is mixed, with 
growing evidence that African Americans are as willing as other groups to participate when 
provided an equal opportunity.14-18 For example, a meta-analysis of 20 health research studies 
with approximately 70,000 participants found that African Americans and Hispanics were just as 
willing as their white counterparts to participate in health research when invited.14 The authors 
concluded that “efforts to increase minority participation in health research should focus on 
ensuring access to health research for all groups, rather than changing minority attitudes.”  
Several explanations have been given as to why minorities, and in particular, African 
Americans are not participating in clinical trials. These studies have focused primarily on 
individual-level cultural factors such as mistrust of healthcare professionals because of the US 
Public Health Service Study of Untreated Syphilis in the Negro Male and perceptions of 
racism.19 My goal with this dissertation and future research is to expand the conversation beyond 
issues of mistrust and racism with regard to minority enrollment in clinical trials.  Other factors, 
if addressed adequately, may reduce disparities in clinical trial participation.  Claudia Baquet, 
MD, summarizes this issue well, “Often physicians don’t discuss the availability of trials with 
minority patients, and there is a lack of information in the community about the potential benefits 
of participating in clinical trials.  In addition, there aren’t enough trials in community settings 
where people affected by disparities often live. Another problem is the design of clinical trials 
themselves — the eligibility criteria are very rigorous, are standardized, and may exclude 






Minority enrollment into clinical trials encompasses a complex set of interacting 
behaviors, structures, and attitudes; thus, I have created a grand conceptual model using 
constructs from the Theory of Planned Behavior and an ecologic framework (Fig. 1).  Adapting 
models by Ford,21 as well as Schultz and Northridge,22 I have included key variables that have 
empirically been shown to affect participation.  I have also added variables that I deem to be 
understudied, yet critically important. The essence of ecologic models is that behavior (e.g., 
clinical trial participation) is affected by multiple circles of influence.  These circles of influence 
include intrapersonal, interpersonal, organizational, community, physical environment, and 
policy.23  The Theory of Planned Behavior has been applied to clinical trials and is well suited 
for explaining the psychological factors that may influence a patient’s decision to enroll in a 
clinical trial.24-26 The theory suggests that attitudes, subjective norm, and perceived behavioral 
control create behavioral intention, which may ultimately lead to the desired outcome or 





Figure 1: Grand conceptual model of minority enrollment in clinical trials 
 
The primary hypothesis of this thesis is that medical mistrust and knowledge of the US 
Public Health Service Study of Untreated Syphilis in the Negro Male are not the underlying 
drivers of low minority participation in clinical trials. Instead, I posit that African Americans are 
willing to participate in medical research and will enroll in clinical trials at rates equivalent to 
other racial and ethnic groups when explicitly invited and given the opportunity to participate.  
For the purposes of this dissertation, I define African American as anyone of African descent, 
living and socialized in the United States, who self-identifies as African American; I do not 
examine within group differences in clinical trial participation (e.g., blacks born in the Caribbean 
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Chapter 2: Willingness of African Americans to Participate in Clinical Trials 
Abstract 
 
Objective:  This study examined predictors of willingness to participate in a clinical trial in a 
sample of 745 African American church members in Southeast Michigan.  
Methods: Two linear regression models were run to evaluate predictors of willingness to 
participate in a clinical trial, controlling for potential confounders.  The first model examined 
demographics and aggregate scales for global trust, patient-provider communication, personal 
benefit, global benefit, and global barriers as predictors of willingness to participate in clinical 
trials.  The second model assessed a combination of aggregate scales and single items as 
predictors of willingness to participate in a clinical trial.   
Results:  The mean score for willingness to participate in a clinical trial was 7.22 on a scale of  
1 – 10, with 10 indicating higher willingness. In Model 1, sex (β=0.43, p=.038), personal benefit 
(β=1.21, p<.001), global benefit (β=1.16, p<.001) and global barriers (β= -0.51 p=.002) were 
significant predictors of willingness to participate in a clinical trial. In Model 2, personal benefit 
(β=0.5, p=.003), global benefit (β=0.79, p<.001), global barriers (β= -0.63, p<.001), amount of 
payment or incentive for participating (β=0.23, p=.011), being involved in decisions about one’s 
health care (β=0.3, p=.013), and trust in the organization conducting the clinical trial (β=1.3, 
p<.001) were significant predictors of willingness to participate in a clinical trial.  
Conclusion:  Our results demonstrate a general willingness among African Americans to 
participate in medical research.  Future efforts to increase enrollment into clinical trials should 




trustworthiness of healthcare organizations among African Americans and their communities 
may also help broaden the pool of African Americans willing to participate in research. 
 
Introduction  
Clinical trials are the mechanism by which new methods of screening, prevention, 
diagnosis, or treatment of disease are developed and tested.1  Clinical trials may benefit 
individual volunteers by providing access to new treatments before they are available to the 
public, and serve the general population by evaluating the safety and efficacy of medical 
treatments, potentially leading to improved treatment options.1  Low participation of racial/ethnic 
subgroups in clinical trials can impede scientific progress by masking disparities in medication 
effectiveness and disease progression across populations.  Underrepresentation of African 
Americans in particular has received considerable attention since 1993 when NIH required that 
all sponsored research include adequate representation of women and minorities.2  While it 
cannot be assumed that African Americans will always derive benefit from clinical trials, it is 
important to ensure that they have equitable opportunities to participate in medical research 
when appropriate and desired.  
Barriers to clinical trial participation among African Americans are well documented and 
include:  medical mistrust, fear of experimentation, lack of awareness of clinical trials and how 
to find them, disparities in patient-provider communication, proximity of clinical trials to 
minority communities, and lack of culturally tailored interventions.3-10 In particular, the US 
Public Health Service Study of Untreated Syphilis in the Negro Male is one of the most well-
known and cited cases of scientific abuse in the African American community, and is commonly 
referenced as a key factor in low willingness of African Americans to participate in research.  




offer of a clinical trial than other groups, or have lower motivation to participate.  These 
assumptions may not be valid and warrant empirical study, as there is some evidence that 
African Americans may be just as willing to participate in health research as their white 
counterparts when provided equivalent invitation.11-13 More research is needed to elucidate the 
factors that influence clinical trial participation among African Americans. A better 
understanding of these factors may enhance future recruitment and retention strategies.    
The objective of this study was to examine predictors of willingness to participate in a 
clinical trial in a sample of African American church members living in Southeast Michigan.  
Specifically, we were interested in the role of benefits, barriers, trust, and patient-provider 
communication on willingness.  
The primary hypotheses were: 
1) Perceived personal benefit of medical research is associated with more willingness to 
participate in a clinical trial.  
 
2) Perceived global benefit of medical research is associated with more willingness to 
participate in a clinical trial. 
 
3) Perceived quality of patient-provider communication is associated with more willingness 
to participate in a clinical trial.  
 
4) Perceived barriers to participating in medical research are associated with less 
willingness to participate in a clinical trial.  
 
5) Perceived trust of healthcare professionals and researchers is associated with more 
willingness to participate in a clinical trial.  
 
6) Knowledge of the US Public Health Service Study of Untreated Syphilis in the Negro 







This study was part of a larger intervention entitled the Body & Soul Clinical Trials 
Project.  The goal of the parent project was to examine the effect of a culturally tailored clinical 
trials education module on African American church members’ willingness to participate in 
medical research and subsequently, their enrollment into the University of Michigan Clinical 
Studies registry.   We chose to work with African American churches because churches are 
trusted social institutions and efficient vehicles for reaching portions of the African American 
community.14  Additionally, faith-based interventions have been effective in improving health 
outcomes for African Americans and for delivering health education programs.15,16  Our project 
provided participants in the control group with health and nutrition information, and participants 
in the intervention group with information about medical research.   
 For the purposes of this paper, we focus on the baseline data of the entire sample, without 
regard to treatment condition, to assess demographic and psychosocial correlates of willingness 
to participate in clinical trials.  The University of Michigan Institutional Review Board approved 
this study. 
Pastors Advisory Board 
A Pastors Advisory Board (PAB) was created to provide feedback about what would be 
feasible and appropriate in a church setting.  The PAB was comprised of seven ordained clergy 
members serving as head pastors or support clergy from small (<200 members), medium (200-
400 members), and large (>600 members) churches.  The group included five men and two 
women; three with Masters of Divinity degrees and one with a PhD in microbiology.  All clergy 
were from local predominantly African American Christian churches and represented the 




The PAB met quarterly in the first year of the project then twice a year after the project was 
implemented.   The PAB provided feedback on several aspects of the project including content 
for recruitment materials, content for our clinical trials video and educational workshops, pre-test 
and post-test survey items, and strategies for successful recruitment and retention.   At each PAB 
meeting, breakfast was served and a $50 Visa gift card was given in return for the pastors’ time 
and feedback.  
	  Church Recruitment 
When recruiting churches, we focused initially on churches with which we had an 
existing relationship from prior health programs.  Additionally, we worked with our Pastors 
Advisory Board, colleagues from the American Cancer Society, and other community-based 
organizations to identify other potential churches within a 60-mile radius of Ann Arbor.   
Church recruitment began with a hard copy mailing of an introductory letter and a study 
brochure to approximately 200 African American churches, followed by telephone calls and e-
mails with interested pastors or health ministry members, and when possible, an in-person 
meeting.  After personal contact was made with the pastor, both the pastor and designated church 
coordinator signed a commitment agreement that outlined roles and responsibilities for the 
church and the study team.  A total of 16 churches were recruited between July 2011 and January 
2012.  Of the churches that declined participation, some of the concerns expressed included not 
having someone in the church to serve as the coordinator, competing church activities (i.e., the 
church was too busy to add another project at the time), time burden of study requirements, and 
generating enough interest for 40 – 60 members to participate.  We used a clustered randomized 




pair-matched churches by size (<200, 200-400, >400) and when possible, by denomination (e.g., 
African Methodist Episcopal, Baptist, Church of God in Christ). 
Participant Recruitment  
The church coordinators were given a goal of recruiting 40 - 60 members from their 
church. The recruitment strategy was left to the discretion of the coordinators; however, we 
developed promotional flyers for display around the church and talking points for church 
announcements. Coordinators were encouraged to recruit individuals by making church 
announcements, posting information on bulletin boards, and by making appeals to groups within 
the church that met regularly (e.g. choir, bible study, and women’s ministry).  
Data Collection 
All study participants completed a self-administered survey at baseline. Graduate level 
research assistants from the University of Michigan were present at each baseline data collection 
session to introduce the study, distribute and collect consent forms and surveys, and to answer 
questions. The baseline survey was 13 pages long, contained 66 questions, and took participants 
approximately 15 - 25 minutes to complete. Two copies of the consent form (one to be returned 
to the study team, the other to be signed and kept by the participant) were attached to each 
survey.  A pen, survey, and a University of Michigan clinical studies brochure and enrollment 
form were included in all baseline survey packets to ensure that both intervention and control 
churches had equal opportunity to enroll into the registry. The University of Michigan Clinical 
Studies registry allows people to create a profile based on interests and health conditions so that 
they can be matched with relevant clinical trials. Once enrolled into the registry, the participants 




which they are alerted of relevant studies.  Enrollment into the registry was the primary outcome 
of the larger study.  
Most baseline data collections were done in a group setting in the churches’ fellowship 
hall.  Most participants completed baseline surveys on Sunday afternoons, immediately 
following church service. In some cases, participants completed surveys in a group setting on a 
different day of the week at the request of the study coordinator (e.g., Saturday morning or after 
Tuesday night bible study).  A few participants completed the survey at home if they wanted to 
be in the study but could not attend the group sessions due to scheduling conflicts.  In these 
cases, the survey was returned to the church coordinator in a sealed envelope and later picked up 
by one of the research assistants from the University of Michigan. All participants completed the 
pen and paper survey independently unless they requested assistance from the study team or 
church coordinator.  For example, a few participants (less than 10) had limited reading skills 
and/or mobility issues with their hands.  In these cases, research assistants from the University of 
Michigan read the survey questions to the participant and/or filled out the form on their behalf. 
Refreshments were provided during each data collection event, and participants were given a $10 
cash bill for completing the baseline survey.    
Measures 
The survey tool assessed past participation in clinical trials and future willingness to 
participate in a clinical trial, as well as knowledge, attitudes, and beliefs about medical research.  
Demographic measures included age, sex, household income, education, and work status. We 
were particularly interested in the roles that perceived barriers, benefits, patient-provider 




factors have been shown to be predictive of willingness and enrollment in past studies, but have 
not been adequately explored.   
Both new and existing single items,17-19 as well as new aggregate scales created by the 
study team were used as predictors of willingness to participate in a clinical trial in the linear 
regression models.  In these cases, the aggregate scale and related single item were not included 
in the same model to avoid multicollinearity. Factor analysis was used to guide the structure of 
the aggregate scales.  The final aggregate scales were created by producing a mean score for all 
items included in scale.   Alpha coefficients for each scale are reported.  
Dependent Variable  
The primary outcome of interest for this paper was self-reported willingness to participate 
in a clinical trial.  The survey question was worded as, “On a scale from 1 to 10, with 1 being not 
at all willing and 10 being very willing, how willing would you be to participate in a clinical trial 
in the future?” Word anchors were used to help give meaning to the number options along the 1 - 
10 scale and included: not at all willing, somewhat unwilling, neutral, somewhat willing, and 
very willing.  
Independent Variables 
Global Trust  
To assess general trust for healthcare providers and related organizations, a 6-item global 
trust scale (α=.76) was created by the research team.  A mean score for global trust was created 
from new items developed for the project and adapted items from past surveys including: 1) I 
trust my primary care doctor; 2) I trust the place where I get most of my medical care; 3) I trust 
my health insurance provider; 4) I trust the University of Michigan; 5) Medical researchers are 




conditions;  and 6) All in all, medical researchers would not conduct experiments on people 
without their knowledge. The response options were: strongly disagree, disagree, neutral, agree, 
and strongly agree.  
Patient-Provider Communication 
Based on prior work in clinical trials and more broadly, general patient-provider 
communication, we proposed that the quality of patient-provider communication might impact 
willingness to participate in clinical trials.20,21  As such, we created a 6-item communication 
scale (α=.91) by adapting items from NCI’s Health Information National Trends Survey to assess 
if quality of patient-provider communication was predictive of willingness to participate in a 
clinical trial.  At the beginning of the patient-provider communication section, participants were 
prompted to respond with the primary care physician or specialist that they saw most often for 
their medical care in mind.  A mean score for patient-provider communication was produced by 
using responses to the following questions: 1) During the past 12 months, how often did doctors, 
nurses, or other health professionals give you the chance to ask all the health-related questions 
you had during a medical appointment; 2) During the past 12 months, how often did doctors or 
other health providers listen carefully to you during a medical appointment; 3) How often did 
they explain things in a way you could understand during a medical appointment; 4) How often 
did they show respect for what you had to say during a medical appointment; 5) How often did 
they spend enough time with you during a medical appointment; and 6) How often did they 
involve you in decisions about your health care as much as you wanted during a medical 
appointment?  Response options were: always, usually, sometimes, never, don’t know, and not 







We assessed perceived personal benefit of a clinical trial as well as perceived global 
benefit (i.e. potential benefit for others, the community, or society at large).  The 3-item personal 
benefit scale was created by the study team (α=.71) and a mean score was produced by using 
responses to the question, “How much would each of the following reasons increase your 
willingness to participate in a clinical trial?”:  1) The benefits of the research for my health; 2) 
Having access to new drugs or treatments; and 3) Getting closer monitoring of my health.  
Response options were: not at all, a little, somewhat, greatly and don’t know.  “The amount of 
payment or incentive for participating” item was evaluated as a separate single item because it 
did not load in factor analysis on either the personal or global benefit factors.  
A 5-item global benefit scale was created by the study team (α= .73).  The mean score for 
global benefit was produced by using responses to the following statements: 1) To determine 
what is best for African Americans health now and for future generations; it’s important for us to 
participate in clinical trials; 2) Participating in medical research is part of my responsibility to the 
African American community; 3) In general, I think that medical research are trying to help 
society; 4) Medical research has improved the health of African Americans; and 5) More African 
Americans would participate in clinical trials if they understood how the research would help 
them or their community. Response options were: strongly disagree, disagree, neutral, agree, 
strongly agree, and don’t know.  
Barriers 
An 11-item global barriers scale created by the study team (α=.84) and a mean score for 




the following reasons decrease your willingness to participate in a clinical trial”: 1) The risks 
involved with the study; 2) The possibility I will receive only a “placebo” or no treatment; 3) 
Additional testing or procedures required because of the clinical trial; 4) The amount of pain or 
discomfort involved; 5) Whether or not my insurance will cover the costs related to the clinical 
trial;  6) The amount of time required to participate; 7) Extra demands on my family members 
because of the study; 8) Travel distance to the medical facility or transportation; 9) Need for 
childcare during medical appointments; 10) Difficulty taking time off from work; and 11) 
Inconvenience or “hassle.” Response options were: not at all, a little, somewhat, greatly, and 
don’t know.  
Knowledge of the US Public Health Service Study of Untreated Syphilis in the Negro Male 
This survey question was worded as, “Have you ever heard of the U.S. Public Health 
Service Syphilis Study at Tuskegee?”  Response options were yes and no. This item was of 
particular interest based on mixed evidence that knowledge of the US Public Health Service 
Study of Untreated Syphilis in the Negro Male is associated with enrollment in clinical trials and 
overall willingness to participate in research. 
Data Analysis 
Frequencies and means were generated for demographic variables and two linear 
regression models were run to evaluate predictors of willingness to participate in a clinical trial, 
controlling for age, sex, household income, work status, and education.  The first model 
examined the impact of demographics and aggregate scales for global trust, patient-provider 
communication, personal benefit, global benefit, and global barriers on willingness to participate 
in a clinical trial.  The second model assessed the impact of a combination of the significant 




clinical trial.  We chose to include single items in Model 2 (e.g., distrust of healthcare 
professionals), as their role on willingness to participate in clinical trials was of particular 
interest and we wanted to ensure that their potential impact was not masked by being included in 
an aggregate scale. We investigated clustering effects within church by running a random 
intercept model, however the random intercept variance was not significant, indicating that there 
is not substantial correlation of individuals within churches, thus a more parsimonious linear 
regression model without random intercept was used. Cases with missing data were removed 
using listwise deletion.  All analyses were conducted with IBM’s SPSS version 20.  
 Results 
We recruited 745 participants from 16 churches in Southeast Michigan. The average 
number of surveys per church was 46, with a range of 19 – 77 surveys per church.  As shown in 
Table 2, the average age was 48 and approximately 68% were female. With regard to educational 
attainment, 5% had less than 11th-grade education; 60% had a high school degree, some college 
or vocational training; and 36% had a 4-year college degree or beyond.  In terms of work status, 
39% of members were employed full-time, 11% were employed part-time, and 50% were not 
working (“not working” included those who were unemployed, retired, students, and/or 
homemakers). The distribution of household income was 51% of households earning less than 
$40K, 31% earning between $40,001 -$80,000, and 18% earning more than $80,001. The mean 
score for willingness to participate in a clinical trial was 7.22 (SD=2.48) for the sample overall, 
with 1 being not at all willing and 10 being very willing.  
Using willingness to participate in a clinical trial as the dependent variable, we ran two 
linear regression models with multiple independent variables. The unstandardized beta 




work status, household income, age, and aggregate scales for patient-provider communication, 
personal benefit, global benefit, global trust, and global barriers on willingness to participate in a 
clinical trial (Ra2=0.26), F (10,455)=17.75, p<.001).  Sex (female β=0.43, p=.038), personal 
benefit (β=1.21, p<.001), global benefit (β=1.16, p<.001) and global barriers (β=-0.51 p=.002) 
were significant predictors of willingness to participate in a clinical trial in Model 1. The second 
model (Table 4) evaluated sex, the personal benefit scale, the global benefit scale, the global 
barriers scale, as well as single items including: amount of payment or incentive for 
participating, being involved in decisions about one’s health, trust in the organization conducting 
the clinical trial, knowledge of the US Public Health Service Study of Untreated Syphilis in the 
Negro Male, and distrust of healthcare professionals (Ra2=0.38, F(10, 497)=31.79, p<.001).  In 
Model 2, significant predictors of willingness to participate in a clinical trial included personal 
benefit (β=0.5, p=.003), global benefit (β=0.79, p<.001), global barriers (β= -0.63, p<.001), 
amount of payment or incentive for participating (β=0.23, p=.011), being involved in decisions 
about one’s healthcare (β=0.3, p=.013), and trust in the organization conducting the clinical trial 
were (β=1.3, p<.001).  
Discussion  
The primary aim of this study was to evaluate predictors of willingness to participate in a 
clinical trial among members of African American churches in Southeast Michigan.  Overall, the 
mean score of 7.22 in willingness to participate in clinical trials indicates a general openness to 
participate in medical research.  Sex was the only demographic variable found to be predictive of 
willingness to participate in a clinical trial in Model 1 and was thus included in Model 2; 
however, sex did not remain significant once the model was expanded.  In Model 1, women on 




other covariates.  While our study focused on willingness to participate in clinical trials versus 
actual enrollment into a clinical trial, females have generally being shown to have lower levels of 
participation in clinical trials than men,22-26 although some studies show that racial/ethnic men 
are underrepresented in research.27,28  Future work should evaluate differences between men and 
women in response to various recruitment methods, interest and enrollment in specific studies, as 
well as retention and attrition rates over time.  
In both models, aggregate scales for perceived personal benefit, global benefits, and 
global barriers were significant predictors of willingness to participate in clinical trials.  In 
particular, perception of how a clinical trial might benefit an individual appears to be an 
important aspect of the decision-making process.  While healthcare providers cannot promise 
that patients will directly benefit from a study or overstate potential positive effects of an 
experimental therapy, special attention should be given to thoroughly explaining the 
hypothesized benefits of a trial during the informed consent process.  Also related to personal 
benefit, the “amount of payment or incentive for participating in a clinical trial,” was associated 
with willingness to participate in a clinical trial in Model 2. This finding is consistent with past 
research that shows that financial reward can be a motivating factor for healthy volunteers when 
deciding to participate in clinical trials.29  
Potential benefits to others and the greater community also appear to be important 
considerations when evaluating willingness. The global benefit scale included items about the 
general benefits of clinical trials to society and in particular, the African American community.  
This finding supports the idea that some people participate in clinical trials for altruistic 
purposes.30,31 That is, even if clinical trial participants do not get a direct benefit from being in a 




treatments and potential cures for future patients.32  In future work, efforts to clearly articulate 
how the research may specifically help individuals and the African American community or 
society at large may enhance enrollment.  This concept is similar to term conditional altruism.  
While not assessed in our study, the idea of conditional altruism is that “willingness to help 
others that may initially incline people to participate in a trial, but that is unlikely to lead to trial 
participation in practice unless people also recognise that participation will benefit them 
personally.”33 As hypothesized, fewer perceived barriers increased one’s willingness to 
participate in a clinical trial.  This finding suggests that more attention should be paid to reducing 
logistical and psychosocial barriers (e.g. amount of time required or perceived risk involved) 
when clinical trials are being designed and implemented. 
The aggregate scale for global trust in Model 1 (mean score for trust of healthcare 
providers and researchers in general) did not predict willingness to participate in a clinical trial, 
nor did the single items in Model 2 about knowledge of the US Public Health Service Study of 
Untreated Syphilis in the Negro Male and distrust in healthcare professionals.  However, the 
single item “trust in the organization conducting the trial” was a significant predictor of 
willingness in Model 2.  Given that clinical trials are conducted by a variety of organizations for 
which participants do not necessarily have to be patients, this finding shows that organizational 
reputation or perceived trustworthiness matters a great deal. For example, a person can obtain 
their medical care in one place out of geographic convenience or insurance restrictions, but not 
necessarily trust the institution. Moving forward, it will be important for healthcare organizations 
to increase their trustworthiness among African Americans, which will include building and in 
some cases mending relationships with African American communities which have often felt 




scale was not significant in Model 1, the single item “being involved in decisions about one’s 
health care” was significant in Model 2, further highlighting the need to help patients to be active 
partners in their health care plan, which may include participating in a clinical trial.  
Study strengths and limitations 
While other studies that have evaluated willingness of African Americans to participate 
in research broadly, our study is one of the first efforts to assess willingness to participate in 
research in a large sample of African Americans from diverse denominations and church 
environments.  Given the growing number of researchers who are partnering with African 
American faith-based institutions to deliver health interventions and to recruit for studies, a 
better understanding of the attitudes and beliefs of this population may inform future projects. 
Additionally, our survey items covered a broad range of potential factors that may affect 
willingness to participate in research including: quality of patient-provider communication, 
personal and community benefit, trust, and barriers.  The diversity of survey questions provides 
rich insight into the reasons why African Americans may or may not be participating in medical 
research.  Building upon prior community outreach efforts and relationships with health 
ministries in black churches, we worked collaboratively with church coordinators and our 
Pastors Advisory Board to ensure that our project would be well received by local churches.  
Several limitations should be noted.  The sample of churches invited to participate in this 
study were not randomly selected, therefore there may be a degree of selection bias both at the 
individual and church level.  All of the churches were located in Southeast Michigan and the 
majority of participants were female, thus results may not be generalizable to other parts of the 
country or to men overall.  Given that our sample was predominantly African American 




attend church and/or have different religious affiliations or spiritual views.  Additionally, our 
results may not be applicable to non-African Americans.  
The catchment area for churches included Ann Arbor, Ypsilanti, Flint, and Detroit 
Michigan – all areas where the University of Michigan has a strong to modest presence with 
regard to medical and community-based research. Ongoing community work by the University 
of Michigan, brand recognition, and public relations/marketing campaigns may have positively 
skewed results with regard to willingness to participate in clinical trials and perceived benefits of 
participating in medical research.  Conversely, this also could reflect the negative experiences 
that this African American community has had with University of Michigan (i.e., willingness 
could have been higher) if participants interpreted the questions as being primarily relevant to 
clinical trials conducted at the University of Michigan. It is also possible that the participants in 
our study, by the very fact that they volunteered to be in our project, are more likely to volunteer 
for clinical trial in the future.  Furthermore, we were only able to assess hypothetical willingness 
to participate in a clinical trial among African American church members in the community who 
were generally in decent health.  Finally, willingness to participate in a clinical trial may differ 
for African American patients in a clinical setting or for those dealing with chronic or acute 
conditions. 
Conclusion 
In summary, our results demonstrate a general willingness among African Americans to 
participate in clinical trials.   This finding is consistent with other studies showing a growing 
trend of expressed interest among African Americans to be involved in medical research.  For 
example, among 5,979 individuals assessed across five sites, African Americans expressed more 




samples, genetic samples, access to medical records, an overnight stay in a hospital, or use of 
medical equipment.34  Our study findings indicate that future efforts to increase enrollment into 
clinical trials should highlight personal and global benefits, while reducing barriers to full 
participation.  Continued strategies to build trust in healthcare organizations and to engage 
patients in discussions about their health care may also help broaden the pool of African 





1. National Cancer Institute. Cancer Clinical Trials.  
http://www.cancer.gov/cancertopics/factsheet/Information/clinical-trials. Accessed May 
10, 2013. 
2. National Institutes of Health. NIH Policy and Guidelines on The Inclusion of Women and 
Minorities as Subjects in Clinical Research – Amended, October, 2001. 2009; 
http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm. 
Accessed April 23, 2013. 
3. Huang H-h, Coker AD. Examining issues affecting African American participation in 
research studies. Journal of Black Studies. 2010;40(4):619-636. 
4. Joseph G, Dohan D. Diversity of participants in clinical trials in an academic medical 
center: the role of the 'Good Study Patient?'. Cancer. Feb 1 2009;115(3):608-615. 
5. Mills EJ, Seely D, Rachlis B, et al. Barriers to participation in clinical trials of cancer: a 
meta-analysis and systematic review of patient-reported factors. Lancet Oncol. Feb 
2006;7(2):141-148. 
6. Brown M, Moyer A. Predictors of awareness of clinical trials and feelings about the use 
of medical information for research in a nationally representative US sample. Ethnicity & 
health. Jun 2010;15(3):223-236. 
7. Gorelick PB, Harris Y, Burnett B, Bonecutter FJ. The recruitment triangle: Reasons why 
African Americans enroll, refuse to enroll, or voluntarily withdraw from a clinical trial - 
An interim report from the African-American Antiplatelet Stroke Prevention Study 
(AAASPS). Journal of the National Medical Association. Mar 1998;90(3):141-145. 
8. Harris Y, Gorelick PB, Samuels P, Bempong I. Why African Americans may not be 
participating in clinical trials. Journal of the National Medical Association. 
1996;88(10):630-634. 
9. Ford, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations 
to cancer clinical trials: a systematic review. Cancer. Jan 15 2008;112(2):228-242. 
10. Simon MS, Brown DR, Du W, LoRusso P, Kellogg CM. Accrual to breast cancer clinical 
trials at a university-affiliated hospital in metropolitan Detroit. American journal of 
clinical oncology. Feb 1999;22(1):42-46. 
11. Wendler D, Kington R, Madans J, et al. Are racial and ethnic minorities less willing to 
participate in health research? PLoS Med. Feb 2006;3(2):e19. 
12. Durant RW, Legedza AT, Marcantonio ER, Freeman MB, Landon BE. Willingness to 
participate in clinical trials among African Americans and whites previously exposed to 
clinical research. Journal of cultural diversity. Spring 2011;18(1):8-19. 
13. Priddy FH, Cheng AC, Salazar LF, Frew PM. Racial and ethnic differences in knowledge 
and willingness to participate in HIV vaccine trials in an urban population in the 
Southeastern US. International Journal of STD & AIDS. February 1, 2006;17(2):99-102. 
14. Warren N, Charles H. Keep the Faith! Working With African American/Black Churches. 
Health promotion practice. November 1, 2011;12(6):789-794. 
15. DeHaven MJ, Hunter IB, Wilder L, Walton JW, Berry J. Health programs in faith-based 
organizations: are they effective? American journal of public health. Jun 
2004;94(6):1030-1036. 
16. Resnicow K, Campbell MK, Carr C, et al. Body and soul. A dietary intervention 





17. Mainous AG, 3rd, Smith DW, Geesey ME, Tilley BC. Development of a measure to 
assess patient trust in medical researchers. Annals of family medicine. May-Jun 
2006;4(3):247-252. 
18. Moseley KL, Freed GL, Bullard CM, Goold SD. Measuring African-American parents' 
cultural mistrust while in a healthcare setting: a pilot study. J Natl Med Assoc. Jan 
2007;99(1):15-21. 
19. LaVeist TA, Isaac LA, Williams KP. Mistrust of health care organizations is associated 
with underutilization of health services. Health Serv Res. Dec 2009;44(6):2093-2105. 
20. Albrecht TL, Eggly SS, Gleason ME, et al. Influence of clinical communication on 
patients' decision making on participation in clinical trials. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology. Jun 1 2008;26(16):2666-
2673. 
21. Eggly SS, Albrecht TL, Kelly K, Prigerson HG, Sheldon LK, Studts J. The role of the 
clinician in cancer clinical communication. Journal of health communication. 2009;14 
Suppl 1:66-75. 
22. Harris DJ, Douglas PS. Enrollment of Women in Cardiovascular Clinical Trials Funded 
by the National Heart, Lung, and Blood Institute. New England Journal of Medicine. 
2000;343(7):475-480. 
23. Du W, Gadgeel SM, Simon MS. Predictors of enrollment in lung cancer clinical trials. 
Cancer. Jan 15 2006;106(2):420-425. 
24. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, 
and age-based disparities. JAMA : the journal of the American Medical Association. Jun 
9 2004;291(22):2720-2726. 
25. Sen Biswas M, Newby LK, Bastian LA, Peterson ED, Sugarman J. Who refuses 
enrollment in cardiac clinical trials? Clinical trials (London, England). 2007;4(3):258-
263. 
26. Cook ED, Moody-Thomas S, Anderson KB, et al. Minority recruitment to the Selenium 
and Vitamin E Cancer Prevention Trial (SELECT). Clinical trials (London, England). 
2005;2(5):436-442. 
27. Sullivan PS, McNaghten AD, Begley E, Hutchinson A, Cargill VA. Enrollment of 
racial/ethnic minorities and women with HIV in clinical research studies of HIV 
medicines. J Natl Med Assoc. Mar 2007;99(3):242-250. 
28. Thompson IM, Ankerst DP, Chi C, et al. Assessing Prostate Cancer Risk: Results from 
the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute. April 19, 
2006;98(8):529-534. 
29. Stunkel L, Grady C. More than the money: a review of the literature examining healthy 
volunteer motivations. Contemporary clinical trials. May 2011;32(3):342-352. 
30. Berg SL, Winick N, Ingle AM, Adamson PC, Blaney SM. Reasons for participation in 
optional pharmacokinetic studies in children with cancer: a Children's Oncology Group 
phase 1 consortium study. Pediatr Blood Cancer. Jul 15 2010;55(1):119-122. 
31. Voytek CD, Jones KT, Metzger DS. Selectively willing and conditionally able: HIV 
vaccine trial participation among women at "high risk" of HIV infection. Vaccine. Aug 
18 2011;29(36):6130-6135. 
32. Costenbader KH, Brome D, Blanch D, Gall V, Karlson E, Liang MH. Factors 
determining participation in prevention trials among systemic lupus erythematosus 




33. McCann SK, Campbell MK, Entwistle VA. Reasons for participating in randomised 
controlled trials: conditional altruism and considerations for self. Trials. 2010;11:31. 
34. Cottler LB, McCloskey DJ, Aguilar-Gaxiola S, et al. Community Needs, Concerns, and 
Perceptions About Health Research: Findings From the Clinical and Translational 








Table 2: Demographics and willingness to participate in a clinical trial among African 
American church members in Southeast Michigan. (N=745) 
Age (Mean) 48 
  Sex (%)  
Female 68 
Male 32 
    
Education (%)   
11th Grade or Less 5 
High School, Some College, 
Vocational  60 
4 Year College + 35 
    
Work Status (%)   
Not working  50 
Part-Time 11 
Full-Time 39 
    
Household Income (%)   
Less than $40K 51 
$40,001 to $80,000 31 
$80,001 + 18 
    
Willingness to participate in a 
















Table 3: Multivariate Linear Regression Model 1. Willingness to participate in a clinical 








Sex*  .433 .038 
Education  .29 .152 
Work Status .134 .228 
Household Income -.131 .344 
Age -.004 .515 
Global Trust Scale .179 .352 
Patient-Provider 
Communication Scale -.151 .379 
Personal Benefit Scale* 1.21 <.001 
Global Benefits Scale* 1.64 <.001 
Global Barriers Scale* -.51 .002 
 





Table 4: Multivariate Linear Regression Model 2. Willingness to participate in a clinical 




Sex .33 .076 
Personal benefit scale* 0.5 .003 
Global benefit scale* .78 <0.001 
Global barriers scale* -.63 <0.001 
Amount of payment or incentive 
for participating in a clinical 
trial* .23 .011 
Healthcare providers involve you 
in decisions about your health 
care* .3 .013 
Healthcare providers explain 
things in a way that you can 
understand -.28 .056 
Knowledge of the US Public 
Health Service Study of 
Untreated Syphilis in the Negro 
Male .06 .73 
Distrust of healthcare 
professionals -.05 .558 
Trust in organization conduction 
the trial* 1.32 <0.001 
 




Chapter 3: Racial/ethnic differences in clinical trial enrollment, refusal rates, ineligibility, 
and reasons for decline among patients at sites in the National Cancer Institute’s 




Objective:  This study examined racial/ethnic differences among patients in clinical trial (CT) 
enrollment, refusal rates, ineligibility, and desire to participate in research within the National 
Cancer Institute’s Community Cancer Centers Program (NCCCP) Clinical Trial Screening and 
Accrual Log. 
Methods:  Data from 4509 log entries were evaluated in this study.  Four logistic regression 
models were run using physical/medical conditions, enrollment into a CT, patient eligible but 
declined a CT, and no desire to participate in research as dependent variables.  
Results: Age ≥ 65 (OR=1.51, CI: 1.28 -1.79), males (OR=2.28, CI: 1.92 – 2.71), and non-
Hispanic black race (OR=1.53, CI: 1.2 – 1.96) were significantly associated with more 
physical/medical conditions.  Age ≥ 65 was significantly associated with lower CT enrollment 
(OR=0.83, CI: 0.7 - 0.98).  Males (OR=0.78, CI: 0.65 -0.94) and a higher grade level score for 
consent form readability (OR=0.9, CI: 0.83 - 0.97) were significantly associated with lower 
refusal rates.  Consent page length ≥ 20 was significantly associated with lower odds of “no 
desire to participate in research” among CT decliners (OR=0.75, CI: 0.58 – 0.98).   
Conclusion: There were no racial/ethnic differences in CT enrollment, refusal rates, or “no 
desire to participate in research” as the reason given for CT refusal. However, higher odds of 
physical/medical conditions were associated with older age, males, and non-Hispanic blacks.  




pool of eligible patients for CTs.  Future work should examine the role of co-morbidities, sex, 
age, and consent form characteristics on CT participation.  
 
Introduction 
Cancer is the second leading cause of death in the United States, with approximately 
$201 billion spent each year in direct medical and indirect mortality costs.1   In 2012, it was 
estimated that 1,638,910  people would be diagnosed with cancer and that 577,190 people would 
die from the disease (all types combined).2   As of January 1, 2009,  there were approximately 
12,553,337 people in the United States who had a history of cancer (all types combined),2 yet 
only 3-5% of adults with cancer participate in cancer clinical trials.3 Of those who do participate, 
enrollment rates are lower for minority groups compared to non-Hispanic whites.4  This is a 
growing area of concern because racial/ethnic minorities bear the greatest cancer burden in the 
United States.5 Clinical trials (CTs) are the mechanism by which new methods of screening, 
prevention, diagnosis, and treatment of disease are developed. A better understanding of what 
makes minority recruitment and involvement in CTs successful is critical, as it will help 
maximize research investments, investigator time, patient commitment, trial generalizability, and 
allow research questions that are germane to minority populations to be more relevantly 
addressed.  
Commonly cited reasons for lower CT participation among minorities include: lack of 
awareness, mistrust, cultural barriers, co-morbidities, low literacy, language differences, 
practical obstacles (e.g. childcare, transportation), lack of invitation, CT design, and lack of 
health insurance.6  Given these barriers, it is often assumed that minorities have less interest in 




groups.  These assumptions may not be valid, and warrant empirical study, as there is growing 
evidence that minorities may be just as willing to participate in health research as their non-
minority counterparts when provided an invitation and opportunity.7-9  Other, potentially more 
important, factors may play a role in the CT participation disparity such as: 1) Access/proximity 
of CTs to minority communities; 2) Readability and length of consent forms; 3) Provider bias in 
offering CTs; 4) Eligibility criteria, and 5) Regional impact on CT attitudes.   
To explore these issues, the NCCCP implemented a Clinical Trials Screening and 
Accrual Log designed to track cancer patients at NCCCP sites who were screened and enrolled 
into selected NCI Cooperative Group treatment and cancer control CTs.  The NCCCP sites 
selected trials for the log based on the majority of sites having access to the trial and the cancer 
type being studied.  A primary goal of the log was to identify challenges to trial accrual and to 
provide information about successful practices to address them, including those for recruiting 
under-represented populations into CTs.10,11  Additionally, implementation of the log has 
allowed NCCCP sites to: 1) Monitor enrollment rates over time; 2) Identify gaps in available 
CTs; 3) Enhance awareness of patient and physician reasons for declining trial participation in 
order to address them; and 4) Raise the visibility and importance of CTs within community 
cancer centers.12	  	  Another paper describes the general details and trends of the log.13 
The objective of this paper was to specifically examine racial/ethnic differences among 
patients in the following areas: CT enrollment, refusal rates, ineligibility, and desire to 
participate in research. A better understanding of these issues may inform future CT recruitment, 






NCCCP Clinical Trial Screening and Accrual Log Data Set 
In 2008, the Clinical Trial Screening and Accrual Log was developed and piloted at 15 of 
the original 16 NCCCP sites. It officially launched in 2009 and later opened to the additional 14 
sites that joined the program in 2010, for a total of 29 sites entering data.  For the purposes of 
this paper, data from 2009 – 2012 were used in the analyses. Full details about the development 
and implementation of the log are reported elsewhere.12 Items in the log include demographic 
information such as age, race, ethnicity, and sex; methods for identifying patients for CTs (e.g., 
chart review or cancer registry); whether the patient enrolled into the CT; reasons for 
ineligibility; patient-related reasons for declining a CT; and physician-related reasons for not 
offering a CT to an eligible patient.  
Procedures 
Log entries were completed by members of the research team (e.g., a study coordinator or 
research nurse).  Data from the log was reported to the NCI via an online reporting system on an 
ongoing basis.  To determine how race/ethnicity would be categorized on the logs, guidelines 
from the Office of Management and Budget were followed.14  For this paper, race/ethnicity was 
collapsed into one variable with five categories: non-Hispanic white, non-Hispanic black, 
Hispanic, Asian, and other.  The other category included American Indian or Alaska Native, and 
Native Hawaiian or Other Pacific Islander.  To avoid potential overlap of categories, logs that 
had “more than one race” selected were excluded from the analyses. Additionally, if a patient 
was Hispanic and a racial category, we treated them as Hispanic. Only logs with complete 
race/ethnicity data were included in our analyses, thus logs with unknown ethnicity or race, or 





A total of 4509 log entries were collected on cancer patients screened from March 2009 
through May 2012.  Sample sizes for analyses ranged from 4184 – 4509 depending on which 
covariates were used. Log entries comprised patients screened for at least one of 27 trials open at 
various times during the data collection period, with most being treatment trials (81.5%).  By 
cancer type, the most common trials were of breast (25.9%), colorectal (22.2%), and 
genitourinary (18.5%) cancers. The most common methods for identifying patients for screening 




Four dependent variables were evaluated and included physical/medical conditions, 
enrollment into a protocol, patient was eligible but declined participation, and no desire to 
participate in research.  A priori, we were interested in examining reasons why patients were 
ineligible for a CT, with an assumption that co-morbidities would be the driving force behind 
ineligibility.  The full question was worded as, “If the patient did not meet trial eligibility 
criteria, indicate the reason why (select all that apply): 1) Abnormal labs; 2) Abnormal organ 
function; 3) Co-morbidities; 4) Does not meet biomarker testing criteria; 5) Insufficient or 
unavailable pathologic samples for study; 6) Patient had progressive disease; 7) Performance 
Status; 8) Prior Therapy; 9) Second Cancer;  and 10) Time requirement.  A binary variable for 
physical/medical conditions was computed by summing responses to the items: abnormal labs, 
abnormal organ function, co-morbidities, progressive disease, and performance status.  A patient 




and were therefore not considered eligible for a CT.  Patients with no conditions would receive a 
“no” for physical/medical conditions. The enrollment question was worded as, “Did the patient 
enroll in the protocol (yes/no)?”  The patient was eligible but declined participation item was a 
part of a larger question written as, “If the patient did not enroll in the protocol, indicate the 
reason why (select only one): 1) Patient did not meet trial eligibility criteria, 2) Patient was 
eligible but declined participation, 3) Patient was eligible but the MD declined to offered 
participation, and 4) Patient was eligible but started treatment prior to completion of screening.  
Lastly, the item no desire to participate in research was one of 22 social, attitudinal, and/or 
logistical response options to the question, “If the patient was eligible, but the patient declined 
participation, indicate the patient-related reason why (select all that apply).”  Given our specific 
interest in racial and ethnic differences in no desire to participate in research as the reason given 
for CT refusal, this was the only response of the 22 choices selected to be a dependent variable 
and included in analyses. 
Independent variables 
Demographic 
Age, sex, race, and ethnicity were treated as potential confounders.  Age was recoded into 
a binary variable of < 65 and ≥ 65, with the reference group being those under 65.  Sex was 
coded as male and female, with females serving as the reference group.  Finally, race and 
ethnicity were coded as non-Hispanic white, non-Hispanic black, Hispanic, Asian, and other, 
with non-Hispanic whites as the reference group.  The “other” category included American 
Indian, Alaska Native, Native Hawaiian, and Pacific Islander.  For all demographic and other 





Region of Country 
A regional variable was computed to specify the area of the country for which the 
NCCCP sites were located.  Following U.S. Census guidelines, regions were categorized as 
West, Midwest, South, and Northeast, with the West serving as the reference group. 
Informed Consent Characteristics 
We were interested in the role of page length and grade level readability on CT 
participation.  It should be noted that page length and readability were not asked on the log, but 
rather, calculated independently by evaluating the NCI Cooperative Group version of the consent 
form. Continuous and categorical variables for page length were created by counting the number 
of pages of the consent forms for each of the 27 CTs included in the log. We selected a cutoff 
point of 20 pages to create a binary variable for page length coded as < 20 pages and > 20 pages. 
To assess readability of the consent forms, a Simple Measure of Gobbledygook (SMOG) score 
was generated using Readability Software by MicroPower and Light Co.16  
Data Analysis 
Frequencies and means were generated to assess how demographic, consent form, and 
regional variables were distributed.  Chi square tests were used to compare patient racial/ethnic 
group differences by CT enrollment, refusal rates, ineligibility, and the medical reasons for 
ineligibility (e.g. abnormal labs or co-morbidities).  Logistic regression was used to assess the 
effect of race/ethnicity, age, sex, region, consent form length, and consent form readability on 
four dichotomized dependent variables including physical/medical conditions, enrollment into a 
CT, patient eligible but declined participation, and no desire to participate in research as the 
reason given for CT refusal.  All analyses were done with the full sample of log data. Correlation 




correlated (i.e., a Pearson’s r ≥ 0.7). Considering the fact that patients are nested within hospitals, 
and hospitals are nested within regions, we treated the hospital as a random effect and region as 
fixed effect to adjust for potential similarity of patients within hospital, as well as potential 
similarities of hospitals within a region. All logistic regression models with random effects were 
run using the GLIMMIX Procedure within SAS 9.3.  
Results 
Demographic, log, and consent form characteristics 
As shown in Table 5, the mean age was 62, with approximately 57% of patients being 
under the age of 65 and women comprising 68% of the sample.  With regard to race/ethnicity, 
78% were non-Hispanic white, 13% were non-Hispanic black, 4% were Hispanic, 4% were 
Asian, and 1% was classified as other (e.g. American Indian, Alaska Native, Native Hawaiian or 
Pacific Islander). The average consent form page length was 17 pages (range of 3-50 pages), 
with 60% of consent forms being less than 20 pages. The average SMOG reading score for the 
consent forms was 10th grade (range of 8 – 12 grade).  With regard to geographic region of the 
country, 31% of patients were located in the West, 30% in the South, 21% in the Northeast, and 
19% in the Midwest. 
Chi Square Analyses 
As shown in Table 6, chi square tests indicate a significant association between the 
patient’s race/ethnicity and enrollment into a CT. Asians had a significantly lower proportion of 
CT enrollment.  The chi square test also indicates a significant association between 
race/ethnicity, CT ineligibility, and co-morbidities. Non-Hispanic blacks had a higher proportion 
of not meeting eligibility criteria for a CT and having co-morbidities.  There were no significant 




research” as the reason for given for declining a CT, or other medical reasons for ineligibility 
(e.g. abnormal labs).  
Logistic Regression Models 
Using physical/medical conditions, enrollment into a CT, patient was eligible but 
declined CT, and “no desire to participate in research” as dependent variables, we ran four 
logistic regression models with multiple independent variables. The odds ratios and confidence 
intervals are reported in Tables 7 and 8. In Model 1, variables significantly associated with 
physical/medical conditions (i.e., health conditions that would make a patient ineligible) included 
age > 65 (OR=1.51, CI: 1.28 -1.79), males (OR=2.28, CI: 1.92 – 2.71), and non-Hispanic black 
race (OR=1.53, CI: 1.2 – 1.96).  In Model 2, the only variable significantly associated with lower 
enrollment into a CT was age > 65 (OR=0.83, CI: 0.7 - 0.98).  In Model 3 (Table 9), variables 
significantly associated with eligible patients less likely to decline a CT included males 
(OR=0.78, CI: 0.65 -0.94) and a higher SMOG score (i.e., written at a higher grade level) on the 
consent form (OR=0.9, CI: 0.83 - 0.97).  Finally, in Model 4 (table not shown), the only variable 
significantly associated with fewer instances of “no desire to participate in research” as the 
reason for decline was consent page length > 20 pages (OR=0.75, CI: 0.58 – 0.98). 
Discussion 
The primary aim of this paper was to examine, via the NCCCP Clinical Trial Screening 
and Accrual Log data, racial/ethnic differences in patient enrollment into a CT, rates of CT 
refusal, CT ineligibility, and desire to participate in research.  Model 1 evaluated the association 
of age, sex, and race/ethnicity with physical/medical conditions.  Being over the age of 65, being 
male, and being non-Hispanic black were all significantly associated with higher odds of 




physical/medical conditions item.  Future work should examine how to design CTs that are more 
tolerable for patients with co-morbidities, which may include loosening the eligibility criteria to 
widen and diversify the pool of candidates.  Another point of consideration is how patients are 
cared for prior to getting a cancer diagnosis and how their co-morbidities are managed in 
general. Better management and earlier identification of co-morbid conditions prior to and 
during cancer treatment may improve CT participation for men, those over 65, and blacks in 
particular, while also improving cancer survival rates over time.17,18	   
With regard to patient CT enrollment, there were no racial/ethnic differences in the 
second logistic regression model. While the chi square analysis initially showed a significantly 
lower proportion of Asians enrolling into a CT, this effect was no longer significant once race 
was evaluated in a logistic regression model that controlled for region and site.  In particular, 
there was no black/white difference in CT enrollment after controlling for region, site, age, sex, 
consent form length, and SMOG readability. Our finding is consistent with other studies that 
have demonstrated that disparities in willingness to participate in research and actual 
participation are often reduced or eliminated when participants have equal access to participate 
and when they are explicitly offered a CT.7,19 Also notable is that consent page length was not 
associated with enrollment into a CT, which is consistent with other studies.20  
Older age (≥65) was associated with lower enrollment into a CT. This finding is not 
surprising, as several studies have shown that older cancer patients are under-represented in CTs, 
despite the fact that many cancers are diagnosed in patients over the age of 65 and that age alone 
is not a valid reason to exclude patients from CTs.21,22  It is notable that in the NCCCP Clinical 
Trial Screening and Accrual Log data set, approximately 43% of CT enrollees were over age 65.  




geriatric assessment tools that may help determine if a patient can tolerate a CT, and ways to 
educate older patients about the option of CTs.23  
Among patients that were eligible, but declined a CT, there were no racial/ethnic 
differences in refusal rates, although males were less likely than females to decline participation.  
While it not clear why this may be the case, some potential explanations include differences in 
the characteristics of the specific CTs offered to men vs. women, male comfort with research in 
general, or how, if at all, providers communicate differently to men about their treatment options, 
which may include a CT.  Surprisingly, as SMOG readability score for consent form increased 
(i.e., as the grade level at which the form was written increased), CT refusal among eligible 
patients decreased.  Since there is limited information on the role of consent form readability and 
CT participation, more research is needed to better understand this relationship.24,25  It should be 
noted that the most common reasons that MDs declined offering a CT to an eligible patient were 
preference for standard of care (49%) and concerns about the patient’s ability to tolerate a CT 
due co-morbidities/frailty (27%). 
 Finally, there were no racial/ethnic differences in “no desire to participate in research” as 
the reason given for declining a CT.  However, consent page length ≥ 20 was associated with 
lower odds of “no desire to participate in research” among CT decliners.  This finding is 
somewhat counter intuitive. More research is needed to better understand the relationship 
between consent form page length and CT participation.  It should be noted that NCI has 
launched a transformed informed consent document template in an effort to address patient 
burden and to enhance participant understanding.  This template includes decreases in page 





Strengths and Limitations 
This study evaluated a large data set of Clinical Trial Screening and Accrual Log entries 
from geographically, racially, and ethnically diverse patients from 29 cancer centers in the 
NCCCP, with race and ethnicity percentages of the logs mimicking the 2010 Census data.27  
Continual assessment and monitoring of sites’ CT accrual via the logs provided a rich data set to 
evaluate the impact of race/ethnicity on different aspects of CT participation.  It is possible that 
this consistent tracking of CT trends was an important factor in equivalent participation among 
whites and blacks in particular.  More work is needed to intervene early with patients having co-
morbid conditions and other under-represented groups in cancer CTs to maximize participation. 
Limitations of this study include differences in how the log was implemented at each site. 
For example, some sites were more consistent than others with regard to filling out the log and 
entering data to the NCI online reporting tool.  Additionally, the log was revised over time to 
improve usability and to reduce the time burden for staff, thus earlier versions may have had 
more incomplete, inconsistent, or written in log entries that were later reclassified for analysis by 
log administrators.  Despite the fact that each trial had specific screening criteria to help guide 
providers in identifying eligible patients, it is possible that some patients were never identified 
and captured on the log; thus, the true number of potentially eligible patients is not known and 
may have biased the results.  Moreover, there was some missing data for race/ethnicity (~13% of 
all logs) and a limited number of Hispanic patients, which may have biased the results and 
limited our ability to generalize the findings.  
While we did not fully explore physician characteristics and patient CT participation, the 
primary reasons that MDs declined offering a CT to an eligible patient were preference for 




morbidities/frailty.  It should be noted that we did not have objective measures to confirm if such 
concerns were valid (e.g., if a patient was actually too ill to participate in a trial), as all log data 
were self-report and completed by a member of the study team.  Future work should explore 
how, if at all, physician preference impacts a patient’s decision to enroll into a CT, the 
physician’s reasons for not offering CTs to eligible patients (e.g. preference for standard 
treatment), and whether a patient’s race/ethnicity influences patient-provider communications 
about CTs and other treatment options.  
Conclusions 
In summary, there were no racial/ethnic differences among eligible patients in CT 
enrollment, refusal rates, or “no desire to participate in research” as the reason given for CT 
refusal within NCCCP’s Clinical Trial Screening and Accrual Log data set.  However, higher 
odds of physical/medical conditions were associated with older age, males, and non-Hispanic 
blacks.  Future work should examine the role of demographics and consent form characteristics 
on CT participation.  In particular, the role of co-morbidities warrants more attention, especially 
with regard to minorities. Future work should explore how better management of a patient’s 
health before a cancer diagnosis (through primary care), as well as improved management of 
these conditions during cancer treatment will impact the future pool of eligible patients.  
Additionally, it is possible that more Phase 4 trials are needed to evaluate how FDA approved 
cancer therapies are tolerated in cancer patients with co-morbidities over time.  A better 
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Table 5: Demographic, log, and consent form characteristics for the full sample (N=4509).  
 
 % n 
Age  62 (mean) 4467 
    < 65  57 2546 
    ≥ 65  43 1921 
Sex   4509 
  Female 68 3060 
  Male  32 1449 
Race and Ethnicity   4225 
   Non-Hispanic White 78 3303 
   Non-Hispanic Black  13 532 
   Hispanic 4 163 
   Asian 4 175 
   Other 1 52 
Logs by Region of the Country    
   West 31 1378 
   Midwest 19 854 
   South 30 1345 
   Northeast 21 932 
SMOG Readability of Consent Forms  
10 
(mean grade)  
4509 
Page Length of Consent Forms  17 (mean) 4509 
   < 20 pages  60 2716 
   ≥ 20 pages   40 1793 
Clinical Trial by Type   
  Treatment 82  
  Symptom management 11  
  Prevention 4  
  Other 3  
Trials by Most Common Cancer Type   
Breast 26  
Colorectal 22  










Table 6: Breakdown of enrollment, refusal, physical/medical conditions and reasons for 
MD not offering a trial by demographics (N=4509). 
 % n P-value 
Patient enrolled into a CT*   0.007 
   Overall enrollment rate for full sample 18 816  
   Non-Hispanic White 20 663  
   Non-Hispanic Black  18 94  
   Hispanic 22 35  
   Asian* 10 17  
   Other 14 7  
Patient eligible but declined CT    0.114 
   Non-Hispanic White 22 713  
   Non-Hispanic Black  21 112  
   Hispanic 21 32  
   Asian 13 23  
   Other 17 12  
Patient did not meet eligibility criteria*   0.004 
   Non-Hispanic White 50 1328  
   Non-Hispanic Black*  56 248  
   Hispanic 49 70  
   Asian 58 91  
   Other 54 21  
“No desire to participate in research” as reason for decline    0.785 
   Non-Hispanic White 7 250  
   Non-Hispanic Black  9 46  
   Hispanic 9 13  
   Asian 6 10  
   Other 6 4  
Co-morbidities ineligibility*   <.001 
   Non-Hispanic White 11 337  
   Non-Hispanic Black * 16 85  
   Hispanic 6 12  
   Asian 6 11  
   Other 10 2  
Abnormal labs ineligibility    0.215 
   Non-Hispanic White 2 76  
   Non-Hispanic Black  4 19  
   Hispanic 3 4  
   Asian 3 3  
   Other 4 3  
 






 Table 6 (continued): Breakdown of enrollment, refusal, physical/medical conditions and 
reasons for MD not offering a trial by demographics (N=4509).  
 % n P-value 
Abnormal organ function ineligibility    0.241 
   Non-Hispanic White 1 35  
   Non-Hispanic Black  2 9  
   Hispanic 2 3  
   Asian 2 3  
   Other 3 2  
Performance status ineligibility   0.272 
   Non-Hispanic White 2 69  
   Non-Hispanic Black  3 15  
   Hispanic 1 1  
   Asian 1 1  
   Other 2 1  
Disease progression ineligibility   0.498 
   Non-Hispanic White 3 89  
   Non-Hispanic Black  4 19  
   Hispanic 2 3  
   Asian 3 5  
   Other 0 0  
Patient was eligible but MD declined to offer participation   0.024 
   Non-Hispanic White 16 409  
   Non-Hispanic Black  13 57  
   Hispanic 12 15  
   Asian 21 33  
   Other* 27 12  
   Age   0.374 
    ≥65 16 253  
   < 65 16 317  
   Sex   < .001 
   Males 12 135  
   Females* 17 439  
 











Table 7: Multivariate Logistic Regression Model 1: Physical/medical conditions as the 
reason for ineligibility by demographic characteristics (N=4184) 
  Odds Ratio CI P-value 
 Age ≥ 65 (ref, <65)* 1.51 1.28 – 1.79 <0.001 
Males (ref, females)* 2.28 1.92 – 2.71 <0.001 
Race and Ethnicity*   0.005 
Non-Hispanic White (ref)  1.0    
Non-Hispanic Black*  1.53 1.20 - 1.96  
Hispanic 0.66 0.4 - 1.11  
Asian 0.85 0.51 - 1.53  
Other 1.1 0.45 - 2.71  
 
*Statistically significant, p < .05 
 
 




Table 8: Multivariate Logistic Regression Model 2: Enrollment into a CT by demographic, 
region, and consent form characteristics (N=4184) 
  Odds Ratio  CI P-value 
Age ≥ 65 (ref, < 65)* 0.83 0.7  – 0.98 0.03 
Males (ref, females) 1.12 0.93 – 1.35 0.24 
Race and Ethnicity   0.18 
Non-Hispanic White (ref)      
Non-Hispanic Black 0.83 0.64 - 1.08  
Hispanic 1.33 0.86 – 2.04  
Asian 0.62 0.34 – 1.14  
Other 0.92 0.38 – 2.23  
Consent Form Length   0.78 
≥ 20 pages (ref, < 20 pages) 0.98 0.81 – 1.16  
Consent Readability   0.4 
SMOG score 0.97 0.89 - 1.05  
Region of Country   0.45 
West (ref)    
Midwest 1.06 0.38 - 2.99  
South 0.45 0.13 – 1.54  
Northeast 1.04 0.34 – 3.23  
 
*Statistically significant, p < .05 
	  




Table 9.  Multivariate logistic Regression Model 3: Patient eligible but declined a CT by 
demographic, region, and consent form correlates (N=4184) 
  
Odds 
Ratio 95% CI 
 
P-value 
Age ≥ 65 (ref, < 65) 0.86 0.73 – 1.01 .07 
Males (ref, females)* 0.78 0.65 – 0.94 .001 
Race and Ethnicity     .78 
Non-Hispanic White (ref)    
Non-Hispanic Black 1.05 0.82 - 1.35  
Hispanic 0.97 0.63 - 1.49  
Asian 0.85 0.51 – 1.44  
Other 1.44 0.68 – 3.04  
Consent Form Page Length   .28 
≥ 20 pages (ref, < 20 pages) 0.91 0.77 - 1.08  
Consent Readability*   .005 
SMOG score 0.9 0.83 – 0.97  
Region of Country   .45 
West (ref)    
Midwest 0.83 0.36 – 1.91  
South 0.7 0.27 – 1.81  
Northeast 1.42 0.59 – 3.42  









Objective: This study examined predictors of enrollment in the University of Michigan Clinical 
Studies Registry in a sample of 745 African Americans from 16 churches in Southeast Michigan. 
Methods: Our study is part of a larger intervention called the Body and Soul Clinical Trials 
Project. The parent project enrolled churches to either receive a clinical trial education program 
(intervention) or education about healthy eating (control). Study participants recruited from the 
churches filled out a baseline survey and were given educational programs. We examined the 
baseline data of the entire sample to determine predictors of enrollment in the University of 
Michigan Clinical Studies registry. We ran three logistic regression models to evaluate predictors 
of enrollment in the registry, each controlling for treatment condition (i.e., intervention or control 
churches).  
Results: In total, 60 people enrolled in the registry over the 1-year period. In all three models, 
treatment condition was a significant predictor of enrollment. Demographic variables were not 
significant predictors of enrollment, nor were baseline aggregate scales for patient-provider 
communication, personal and global benefits, global barriers, or global trust. However, baseline 
willingness to participate in a clinical trial (OR = 1.17, CI: 1.01–1.36; P = 0.04) and 
inconvenience/hassle associated with a clinical trial (OR = 0.73, CI: 0.55-0.98; P = 0.03) were 




Conclusion: Certain baseline characteristics, including willingness to participate in a clinical 
trial and perceptions of inconvenience/hassle associated with a clinical trial significantly 
predicted enrollment in a university-based registry. More work is needed to test the effectiveness 
of delivering clinical trial education programs in faith-based settings and how, if at all, African 
Americans may view registries differently than other racial and ethnic groups.  
 
Introduction  
 Clinical trials are the gold standard for testing new methods of screening, preventing, 
diagnosing, and treating various medical conditions. Each year, thousands of clinical trials are 
opened at medical centers across the United States,1 yet estimates of clinical trial participation 
among all adults in the U.S. (across diseases) range from as low as 1% to as high as 11%, despite 
ongoing campaigns to inform the public about research.2,3 Low participation in clinical trials is a 
public health concern because many studies close early due to low accrual,4-6 resulting in the 
inefficient use of patient and investigator time, limited generalizability of findings, and 
ineffective spending of research dollars.7 Women, rural populations, older adults, and 
racial/ethnic minorities have historically been underrepresented in clinical trials.8-10 In particular, 
African Americans, who suffer disproportionately from cancer, diabetes, hypertension, and heart 
disease compared with whites, remain underrepresented in clinical trials for these conditions.8,11-
13  
Common barriers to clinical trial enrollment among African Americans include medical 
mistrust, fear of experimentation, co-morbid conditions, limited awareness about medical 
research, and logistical burdens associated with participating in clinical trials (e.g., extra time, 




provider communication, a positive relationship with one’s healthcare provider, perceived 
personal benefit, and feelings of altruism.16 Despite the need to include more African Americans 
and other racial and ethnic groups in medical research, there is paucity of research on the most 
effective recruitment strategies for increasing enrollment in clinical trials.17 Traditional methods 
of recruiting participants include: mailed, telephone, and/or in-person invitations based on 
medical record or disease registry audits; flyers on hospital and community bulletin boards; paid 
advertisements in print, online, or television media; word of mouth; hiring study coordinators 
and recruiters of the same demographic as the population being studied; and on-site recruitment 
at public events or in clinical settings.18-20 Participants can also find clinical trials on websites 
like ClinicalTrials.gov, through disease-specific organizations like the National Cancer Institute, 
or by contacting local medical centers.  
Over the last 10 years, the use of registries as a method to recruit study participants has 
grown, although the efficacy of such registries is under-researched. For example, 
RegistryMatch.org was the first national registry to promote clinical trials across NIH-funded 
Clinical and Translational Science Award (CTSA) programs.21 Created in 2008, the goal of 
ResearchMatch.org is “to bring together people who are trying to find research studies and 
researchers who are looking for people to participate in their studies.”22 Investigators are able to 
post approved studies to the website and subsequently recruit volunteers from across the U.S. for 
their studies. As of July 22, 2013, ResearchMatch.org had approximately 40,000 volunteers in 
the registry, with 300 studies listed and 80 institutions represented. 
In the same spirit, a small number of research institutions (< 10), including the University 
of Michigan, have created local registries to match potential volunteers with clinical trials at their 




ClinicalTrials.gov) or postings to hospital websites, these newer “opt-in” registries allow healthy 
volunteers and patients with health conditions to proactively enroll in the registry. A study team 
member may contact volunteers if a clinical trial opens and they meet the eligibility criteria. For 
example, the University of Michigan registry (UMClinicalStudies.org) allows people to create a 
profile based on their interests and health conditions. As of July 22, 2013, the 
UMClinicalStudies.org website had approximately 14,000 volunteers in the registry, with 
approximately 9% being African American. To enroll in the registry, volunteers complete a 
consent form and a questionnaire about their medical conditions, demographics, site preferences 
for studies (e.g., Ann Arbor campus), and other interests (e.g., stress or weight management). 
Volunteers determine the method (letter, phone, or e-mail) and frequency (as available, weekly, 
monthly) by which they are contacted. After the profile is created, they begin receiving 
“personalized study recommendations,”24 thus eliminating the need for a health care provider to 
serve as the gatekeeper of this information.  A 2005 study conducted by Beskow et al. found that 
more than 60% of cancer patients preferred that researchers contact them directly about research 
participation rather than checking with their physician first.25   
Additional research is needed to test the efficacy of registries for recruiting more African 
Americans into clinical trials and how, if at all, African Americans view enrolling into a registry 
differently than receiving a direct invitation from their physician to join a clinical trial. Ideally, 
registries help connect community members to health studies at medical centers in their area, 
while also raising awareness about the importance of medical research. The Education Network 
to Advance Cancer Clinical Trials, the National Medical Association, and the National Cancer 
Institute advocate for community-based approaches to increase minority involvement in clinical 




few studies that control for the opportunity to enroll into a registry. Moreover, the role of faith-
based interventions as a means to enhance minority participation in clinical trials has not been 
adequately explored.  
The objective of this study was to evaluate baseline predictors of enrollment in a university-
based registry. The primary hypotheses were: 
1) Enrollment in the registry will be moderated by baseline characteristics including age, 
 sex, education, work status, and household income. 
 
2) Willingness to participate in a clinical trial in the future will predict higher   
       enrollment in the registry. 
 
3) Quality of patient-provider communication will predict higher enrollment in the  
      registry. 
 
4) Knowledge of the US Public Health Service Study of Untreated Syphilis in the Negro 




	   This study is part of a larger intervention entitled the Body & Soul Clinical Trials Project. 
The goal of the parent project was to examine the effect of a culturally tailored clinical trials 
education program on African American church members’ willingness to participate in clinical 
trials and subsequently, their enrollment in the University of Michigan Clinical Studies registry. 
The parent project was built upon two existing programs: Body & Soul: A Celebration of 
Healthy Eating & Living, and the National Medical Association’s Project IMPACT (Increase 
Minority Participation and Awareness of Clinical Trials). Participants in the control group 
received information about healthy eating and participants in the intervention group received 
information about participating in medical research. A manuscript reporting intervention effects 




this paper, we focus on the baseline data of the entire sample and how these variables predict 
subsequent enrollment in the registry over the 1-year intervention period. 
Control Group Protocol 
 The control churches received an adapted version of the national Body & Soul program, 
which promotes fruit and vegetable intake among African American church members. The 
original Body and Soul program used four program pillars: pastoral support, church activities, 
church environment, and peer counseling. We added information on heart disease, cancer, Type 
2 diabetes, stress management, how to read nutrition labels, and healthy eating recommendations 
from the Academy of Nutrition and Dietetics (formerly the American Dietetic Association). This 
additional information was added at the suggestion of our Pastors’ Advisory Board since many 
of their members suffer from chronic diseases and obesity. A website was created for the control 
group with general information about clinical trials and medical research taken directly from the 
University of Michigan Clinical Studies website. 
Intervention Group Protocol 
 The intervention churches received a clinical trials education module that was developed 
from materials from the National Medical Association’s Project IMPACT campaign, feedback 
from our Pastors Advisory Board, and feedback from colleagues at the University of Michigan 
Clinical Studies Registry (UMClinicalStudies.org). The goals of the tailored clinical trials 
module were to: 1) Raise awareness about clinical trials, 2) Discuss the research process, and 3) 
Discuss the role of race and culture in medical research. Given the sensitive nature of medical 
research for some African Americans, we addressed issues related to race and medical 
exploitation but also presented potential positive reasons that African Americans may want to 




Americans over time. Other topics in the module included discussions on epigenetics (the 
concept that the human genome dynamically responds to social and environmental factors such 
as toxins and stress), common terminology (e.g., informed consent, randomization), process for 
developing new therapies (e.g., phase 1–4), and participant rights and protections.  
 Participants in the intervention group watched a short, locally-produced video about 
clinical trials at the University of Michigan that highlighted the need for more African 
Americans to be represented in medical research. This video was shown at the first data 
collection session after the baseline surveys were completed. The video featured three local 
African-American clergy members in Southeast Michigan, three African-American physicians, 
and one African-American clinical trial participant from the University of Michigan Health 
System. A website was created for the intervention group churches with clinical trial and medical 
research information adapted from the National Medical Association’s Project IMPACT. Lastly, 
intervention church members received two e-mail invitations to the join the registry. Those 
without e-mail addresses received a hard copy letter with the same information. 
Educational Workshops for Control and Intervention Churches 
 All workshops (healthy eating for control churches and clinical trials for intervention 
churches) were conducted at the churches and lasted approximately one hour. A one-hour time 
frame was selected based on feedback from the coordinators and the Pastors Advisory Board. 
Brevity of the workshops was particularly important because many church members attend 
church for 2–4 hours on Sundays. Members of the research team (one doctoral candidate and two 
master’s-level graduate students) facilitated the workshops. We initially planned to use a “train 
the trainer” model in which the church coordinators would deliver the educational workshops; 




the Pastors Advisory Board. Many of the coordinators did not have a medical background and 
were not comfortable presenting information about clinical trials or healthy eating, and thus 
requested that the study team conduct the workshops.    
Church Recruitment 
 Church recruitment began with a hard-copy mailing of an introductory letter and a study 
brochure to approximately 200 African-American churches, followed by telephone calls and e-
mails with interested pastors or health ministry members, and when possible, an in-person 
meeting. After personal contact was made with the pastor, both the pastor and designated church 
coordinator signed a commitment agreement that outlined roles and responsibilities for the 
church and the study team. A total of 16 churches (the number determined though sample size 
calculations) were recruited between July 2011 and January 2012. We randomly assigned 
churches to the control group or intervention group. Before randomization, we pair-matched 
churches by size (< 200, 200-400, > 400) and when possible, by denomination (e.g., African 
Methodist Episcopal, Baptist, Church of God in Christ). 
Participant Recruitment  
 The church coordinators were given a goal of recruiting 40 to 60 members from their 
church. The recruitment strategy was left to the discretion of the coordinators; however, we 
developed promotional flyers for display around the church and talking points for church 
announcements. Coordinators were encouraged to recruit individuals by making church 
announcements, posting information on bulletin boards, and by making appeals to groups within 







Baseline and Post-Test Data Collections 
 All study participants completed a self-administered baseline survey and a post-test 
survey at approximately 1-year of follow up. The baseline survey was 13 pages long, contained 
66 questions, and took participants approximately 15–25 minutes to complete. The post-test 
survey was 17 pages long, contained 88 questions, and took participants approximately 20–30 
minutes to complete. Baseline and post-test data collections were done in a group setting in the 
churches’ fellowship hall. Graduate level research assistants from the University of Michigan 
were present at all data collection sessions to distribute and collect surveys and to answer 
questions. Most participants completed the surveys on Sunday afternoons, immediately 
following the church service. However in some cases, participants completed surveys in a group 
setting on a different day of the week at the request of the study coordinator, or completed the 
survey at home if they could not attend the pre-scheduled group session. In these cases, the 
survey was returned to the church coordinator in a sealed envelope and later picked up by one of 
the research assistants from the University of Michigan.  
 All participants completed the pen and paper survey independently unless they requested 
assistance from the study team or church coordinator. For example, a few participants (less than 
10) had limited reading skills and/or mobility issues with their hands. In these cases, research 
assistants from the University of Michigan read the survey questions to the participant and/or 
filled out the form on their behalf. Refreshments were provided during each data collection 
event, and participants were given $10 in cash for completing the baseline and the post-test 







 The baseline survey tool assessed past participation in clinical trials, future willingness to 
participate in a clinical trial, and attitudes about medical research. Both new and existing single 
items26-28 as well as new aggregate scales created by the study team were used as predictors of 
enrollment in the logistic regression models. Factor analysis was used to guide the structure of 
the aggregate scales. The final aggregate scales were created by producing a mean score for all 
items included in scale.  Alpha coefficients for each scale are reported. 
Dependent Variable 
 The primary outcome for this paper was verified enrollment in the University of 
Michigan Clinical Studies Registry. The registry keeper verified enrollment by tracking phone, 
mailed, or the website registrations from January 1, 2012 – June 30, 2013. Mailed enrollment 
forms were identified by the project logo placement in upper right corner of the form. If a 
participant called the 800 number, the registry keeper asked how the caller heard about the 
registry. If “church” was mentioned as the method of hearing about University of Michigan 
Clinical Studies, the registry keeper would then check the caller’s church name against the list of 
churches in the Body & Soul Clinical Trials Project. Website enrollment was tracked through 
special URLs created for the intervention and control churches. The registry keeper and web 
master provided the study team with a list of church members who enrolled by mail, phone, or 









 Age was assessed on a continuous scale, and sex was coded as male and female. Work 
status was categorized into three levels: not working (students, retirees, homemakers), part-time, 
and full-time. Household income was categorized into three levels: less than $40,000; $40,001 – 
$80,000; and $80, 000 plus, and education was categorized by 11th grade or less; high school, 
some college, and vocational training; and 4 year college plus. A dichotomous variable for 
education (< 4 year college and ≥ 4 year college) was used due to the small number of 
participants with an 11th-grade education or less. 
Global Trust  
 To assess general trust for healthcare providers and related organizations, a 6-item scale 
(α = 0.76) was created by the research team based on the following items: 1) I trust my primary 
care doctor; 2) I trust the place where I get most of my medical care; 3) I trust my health 
insurance provider; 4) I trust the University of Michigan; 5) Medical researchers are generally 
honest in telling participants about different treatment options available for their conditions; and 
6) All in all, medical researchers would not conduct experiments on people without their 
knowledge. The response options were: strongly disagree, disagree, neutral, agree, and strongly 
agree. The aggregated mean score was used for analyses.  
Patient-Provider Communication 
 Based on prior patient-provider communication measures, we created a 6-item scale (α = 
0.91) by adapting items from NCI’s Health Information National Trends Survey. At the 
beginning of these items, participants were prompted to respond with the primary care physician 




into an overall mean, were: 1) During the past 12 months, how often did doctors, nurses, or other 
health professionals give you the chance to ask all the health-related questions you had during a 
medical appointment; 2) During the past 12 months, how often did doctors or other health 
providers listen carefully to you during a medical appointment; 3) How often did they explain 
things in a way you could understand during a medical appointment; 4) How often did they show 
respect for what you had to say during a medical appointment; 5) How often did they spend 
enough time with you during a medical appointment; and 6) How often did they involve you in 
decisions about your health care as much as you wanted during a medical appointment? 
Response options were: always, usually, sometimes, never, don’t know, and not applicable.  The 
aggregated mean score was used for analyses. 
 Benefits  
 We assessed perceived personal benefit of a clinical trial as well as perceived global 
benefit (i.e. potential benefit for others, the community, or society at large).  The 3-item personal 
benefit scale was created by the study team (α=.71) and a mean score was produced by using 
responses to the question, “How much would each of the following reasons increase your 
willingness to participate in a clinical trial?”:  1) The benefits of the research for my health; 2) 
Having access to new drugs or treatments; and 3) Getting closer monitoring of my health.  
Response options were: not at all, a little, somewhat, greatly and don’t know.   
 A 5-item global benefit scale was created by the study team (α = 0.73) using the 
following items: 1) To determine what is best for African Americans’ health now and for future 
generations, it’s important for us to participate in clinical trials; 2) Participating in medical 
research is part of my responsibility to the African-American community; 3) In general, I think 




of African Americans; and 5) More African Americans would participate in clinical trials if they 
understood how the research would help them or their community. Response options were: 
strongly disagree, disagree, neutral, agree, strongly agree, and don’t know. We used the 
aggregated mean score of responses for analyses. 
Barriers 
 An 11-item global barriers scale created by the study team (α = 0.84) based on answers to 
following question: “How much would each of the following reasons decrease your willingness 
to participate in a clinical trial?” 1) The risks involved with the study; 2) The possibility I will 
receive only a “placebo” or no treatment; 3) Additional testing or procedures required because of 
the clinical trial; 4) The amount of pain or discomfort involved; 5) Whether or not my insurance 
will cover the costs related to the clinical trial; 6) The amount of time required to participate; 7) 
Extra demands on my family members because of the study; 8) Travel distance to the medical 
facility or transportation; 9) Need for childcare during medical appointments; 10) Difficulty 
taking time off from work; and 11) Inconvenience or “hassle.” Response options were: not at all, 
a little, somewhat, greatly, and don’t know. We used the aggregated mean score of responses for 
analyses.  
Willingness to Participate in a Clinical Trial  
 We queried willingness by asking, “On a scale from 1 to 10, with 1 being not at all 
willing and 10 being very willing, how willing would you be to participate in a clinical trial in 
the future?” Word anchors were used to help give meaning to the number options along the 1–10 






Knowledge of the US Public Health Service Study of Untreated Syphilis in the Negro Male 
 This survey question was worded as, “Have you ever heard of the U.S. Public Health 
Service Syphilis Study at Tuskegee?” Response options were yes and no. This item was of 
particular interest based on mixed evidence that knowledge of the US Public Health Service 
Study of Untreated Syphilis in the Negro Male is associated with enrollment in clinical trials and 
overall willingness to participate in research.29,30  
Treatment Condition 
 A binary variable (control or intervention) was created to differentiate church members in 
the clinical trials education group (intervention) and healthy eating education group (control). 
The control churches served as the reference group.  
Data Analysis 
 Three logistic regression models were run to evaluate predictors of enrollment in the 
University of Michigan Clinical Studies Registry, each controlling for treatment condition. The 
first model examined the impact of demographics on enrollment in the registry. The second 
model examined the impact of aggregate scales for global trust, patient-provider communication, 
personal benefit, global benefit, and global barriers on enrollment in the registry. The third 
model assessed the impact of single items on enrollment in the registry including willingness to 
participate in a clinical trial, inconvenience or hassle associated with a clinical trial, responses to 
the item “participating in research is my responsibility to the black community,” responses to the 
item “I have experienced discrimination in a health care setting,” and knowledge of the US 
Public Health Service Study of Untreated Syphilis in the Negro Male. We chose to include single 
items in model 3 because we were particularly interested in their role with regard to enrollment 




were first done to identify potential predictors of enrollment into the registry (data not reported). 
Only seven items were significant, five of which were evaluated in model 3. Due to small sample 
sizes and multicollinearity, the two items that were dropped were: “Have you been asked to 
participate in a clinical trial, but declined” (only 200 responded yes) and difficulty taking time 
off work (correlated with inconvenience/hassle). Initially, we investigated clustering effects 
within church by running a random intercept model, however the random intercept variance was 
not significant, indicating that there is not substantial correlation of individuals within churches, 
thus a more parsimonious logistic regression model without random intercept was used. Cases 
with missing data were removed using listwise deletion. Finally, interaction effects of age, sex, 
education, work status, and household income on each scale and item were evaluated, but none 
were significant and are not reported. All analyses were conducted with IBM’s SPSS statistics 
software version 20.  
Results 
 By the end of the project, 60 participants had enrolled in the registry. All others were 
coded as not enrolled. Of all of the methods of enrollment (e.g., mail, phone, web), standard U.S. 
mail was the most common way that people signed up for the registry, with more than 90% of 
participants using this method.  We initially recruited 745 participants from 16 churches in 
Southeast Michigan to participate in our study. The average number of baseline surveys per 
church was 46, with a range of 19–77 surveys per church.  At one year follow up, 580 
participants completed the post-test survey for a retention rate of 78%. Reasons for attrition 
included participants who passed away, moved out of the area, left the church, and/or did not 




 As shown in Table 10, the average age was 48, with approximately 68% of the sample 
being female. With regard to education, 5% had less than an 11th grade education; 60% had a 
high school degree, some college, or vocational training; and 36% had a 4-year college degree or 
higher. In terms of work status, 50% were not working (this included unemployed, retired, 
students, or homemakers), 39% were employed full-time, and 11% were employed part-time. 
This distribution of household income was 51% of households earning less than $40K, 31% 
earning between $40,001 - $80,000, and 18% earning more than $80,001. The mean score for 
willingness to participate in a clinical trial was 7.22, and 8% of the sample enrolled into the 
registry.  
 Using enrollment in the University of Michigan Clinical Studies Registry as the 
dependent variable, we ran three logistic regression models with multiple independent variables. 
The odds ratios and confidence intervals are reported in Tables 11–13. The first logistic 
regression model (Table 11) assessed age, sex, education, work status, household income, and 
education on enrollment into the registry, controlling for treatment condition. None of these 
demographic variables were significant predictors of enrollment in the registry, however 
treatment condition was a significant predictor of enrollment (OR=2.68, CI: 1.44 – 5.0). The 
second logistic regression model (Table 12) assessed the role of the baseline aggregate scales for 
patient-provider communication, personal benefit, global benefit, global barriers, and global trust 
on enrollment in the registry. None of the aggregate scales were significant predictors of 
enrollment into the registry, although treatment condition remained significant (OR=2.94, 
CI:1.57 – 5.5).  
 The final logistic regression model (Table 13) assessed willingness to participate in a 




is my responsibility to the black community,” “I have experienced discrimination in a health care 
setting,” and knowledge of the US Public Health Service Study of Untreated Syphilis in the 
Negro Male on enrollment in the registry. Treatment condition (OR=2.86, CI: 1.47 - 5.54), 
willingness to participate in a clinical trial (OR=1.17; CI, 1.01 – 1.36) and inconvenience or 
hassle associated with a clinical trial (OR=0.73, CI: 0.55 – 0.98) were significant predictors of 
enrollment into the registry.  
Discussion 
 The primary aim of this study was to evaluate baseline predictors of enrollment in a 
university-based registry in a cohort of African American church members living in Southeast 
Michigan. In total, 60 church members enrolled into the registry over a 1-year period. None of 
the demographic characteristics (age, sex, household income, work status, and education) nor 
aggregate scales for patient-provider communication, personal benefit, global benefit, global 
barriers or global trust predicted enrollment in the registry. Baseline willingness to participate in 
a clinical trial in the future and inconvenience or hassle associated with a clinical trial were 
significant predictors of enrollment in the registry. That is, higher willingness to participate in a 
clinical trial was associated with higher enrollment into the registry, and stronger perceptions of 
inconvenience or hassle were associated with lower enrollment.  
 Initially, we anticipated that there would be greater challenges with recruiting church 
members into this study, especially given that clinical trials may not be as popular as other health 
behaviors such as nutrition, physical activity, stress management, and weight loss. While we did 
not have challenges recruiting participants into the study, more work is needed to better 
understand how to engage the faith community in discussions about medical research and how to 




African Americans (and other racial and ethnic groups) view recruitment registries is needed. 
During workshops and data collection sessions, church members had questions about the purpose 
of the registry and whether or not they would start getting solicitations from the University of 
Michigan. It is possible that church members viewed the registry as a marketing tool for the 
university and were therefore apprehensive about signing up. The goal of the registry is to match 
interested volunteers with relevant clinical trials and to provide personalized study 
recommendations. Participants who sign up for the registry are indeed more likely to receive 
research-related correspondence from the University of Michigan than the general public. It 
should be noted that formally joining the registry is not necessary to learn about health studies at 
the University of Michigan and other places. Some church members may have chosen to explore 
clinical trials on their own as a result of being in our project, which would not have been 
captured in our survey data.  
Study strengths and limitations 
 Our study is one of the first efforts to assess enrollment in a university-based registry in 
sample of African-American church members from diverse denominations and church 
environments. Given the growing number of researchers who are partnering with African-
American faith-based institutions to recruit for clinical trials, a better understanding of the 
attitudes and beliefs of this population may inform future projects. Additionally, over the course 
of conducting workshops in the churches, several questions from church members about the 
relevance of clinical trials for African Americans and the purpose of the registry were raised, 
which may improve future educational campaigns about medical research, as well as the 




 Several limitations should be noted. The sample of churches and church members invited 
to participate in this study were not randomly selected (this was a convenience sample); therefore 
there may be a degree of selection bias both at the individual and church level. All of the 
churches were located in Southeast Michigan, and the majority of participants were female; thus 
results may not be generalizable to other parts of the country or to men overall. Additionally, 
given the limited number of items that predicted enrollment in the registry, it is possible that we 
did not measure the items or underlying constructs well. It is also possible that we missed people 
that did enroll in the registry due to our tracking system. That is, we were only able to query 
enrollment of participants who mailed back the project-branded forms provided by study team, 
those who called and identified that they heard about the registry from church, or those that 
enrolled via the websites specifically created for the project. It is possible that church members 
joined the registry via the general University of Michigan website or by returning the standard 
enrollment form disseminated to the general public at community events.  
 Finally, it should be noted that enrollment in the University of Michigan Clinical Studies 
Registry is not equivalent to enrolling into a clinical trial, but rather a general proxy of one’s 
interest in learning more about research opportunities. Once a person is enrolled in the registry, 
there needs to be open clinical trials for which the volunteer qualifies (which is not always the 
case) and then, the volunteer needs complete the informed consent process to formally enroll in a 
clinical trial.  
Conclusion 
 This study showed that it is possible to recruit African American church members into a 
university-based registry. However given the modest number of church members who enrolled, 




faith-based settings, and how, if at all, African Americans may view registries differently from 
other racial and ethnic groups. Additionally, future work should examine what happens to 
volunteers after they are enrolled in a registry and whether the existence of a university-based 
registry actually improves enrollment in specific clinical trials across health conditions.  
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Table 10: Baseline demographics of African American church members  (N = 745). 
Age (mean) 48 
Sex (%)  
Male  32 
Female 68 
Work Status (%)  
Not working (retired, students, etc.) 50 
Part-time 11 
Full-time 39 
Household Income (%)  
Less than $40,000 51 
$40,001 - $80,000 31 
$80,001 plus 18 
Education (%)  
11th Grade or less 5 
High school, some college, and/or 
vocational training 
60 







Table 11: Enrollment in the registry by baseline demographics, multivariate logistic 
regression. (n=631) 
 Odds Ratio 95% CI P-value 
Treatment Condition 
(control, ref)* 
2.68 1.44 – 5.0 .002 
Age  1.02 .99 – 1.03 .192 
Sex (males, ref) 1.8 .87 – 3.64 .104 
Education (Less than 4 
year degree, ref) 
.84 .44 – 1.6 .592 
Work Status   .234 
Not working (ref) 1.0   
Part-time 1.08 .41 – 2.83  
Full-time .56 .27 – 1.14  
Household Income   .146 
Less than $40,000 (ref) 1.0   
$40,001 – $80,000 1.81 .91 – 3.6  
$80,001 plus .92 .37 – 2.31   
 






Table 12: Enrollment in the registry by baseline aggregate scales, multivariate logistic 
regression (n=600) 
 Odds Ratio 95% CI P-value 
Treatment condition 
(control, ref)* 
2.94 1.57 – 5.5 .001 
Patient-Provider 
Communication 
1.03 .61 – 1.73 .922 
Personal Benefit .96 .58 – 1.62 .889 
Global Benefit 1.57 .83 – 2.96 .162 
Global Barriers .73 .46 – 1.13 .154 
Global Trust 1.2 .67 – 2.13 .54 
 





Table 13: Enrollment in the registry by individual baseline survey items, multivariate 
logistic regression (n=595) 
 Odds Ratio 95% CI P-value 
 
Treatment condition (control, ref)* 
 
2.86 1.47 – 5.54 .002 
Willingness to participate in a 
clinical trial in the future* 
1.17 1.01 – 1.36 .04 
Inconvenience or “hassle” 
associated with a clinical trial* 
.73 0.55 – 0.98 .03 
Participating in research is my 
responsibility to the black 
community 
.99 0.73 – 1.34 .93 
I have experienced discrimination 
in a healthcare setting 
.81 0.64 – 1.03  .08 
Knowledge of the US Public Health 
Service Study of Untreated Syphilis 
in the Negro Male 
1.9 0.93 – 3.95 .08 
 





Chapter 5: Closing Thoughts and Implications 
The main hypothesis of my dissertation research was that logistical factors such as 
whether patients are offered clinical trials and have access to quality medical care are the 
underlying drivers of racial and ethnic disparities in clinical trial participation; more so than 
factors such as mistrust and perceived racism.  In paper 1, I found that African Americans are 
willing to participate in clinical trials and that willingness to participate in a clinical trial was 
associated with scales for personal benefit, global benefit, and global barriers, as well as the 
amount of payment, trust in the organization offering the trial, and being involved in decisions 
about one’s healthcare; however, knowledge of the US Public Health Service Study of Untreated 
Syphilis in the Negro Male and distrust of healthcare professionals were not associated with 
willingness to participate in a clinical trial.  In paper 2, I found no racial/ethnic differences in 
clinical trial enrollment, refusal rates, or desire to participate in medical research among cancer 
patients; however, ineligibility due to physical/medical conditions was associated with older age, 
being male, and non-Hispanic blacks.  In paper 3, I found that enrollment in the University of 
Michigan Clinical Studies registry was associated with treatment condition, willingness to 
participate in a clinical trial, and perceptions of inconvenience.  Knowledge of the US Public 
Health Service Study of Untreated Syphilis in the Negro Male and distrust of healthcare 
professionals were not associated with enrollment in the registry.   
While I acknowledge that medical mistrust and knowledge of the US Public Health 
Service Study of Untreated Syphilis in the Negro Male are important factors in the narrative of 




that other factors (e.g., co-morbidities and perceptions of benefit for self and community) may be 
equally or more important.  Moving forward, a better understanding of the following areas may 
help reduce disparities in minority participation and warrant more attention.  
Institutional Racism  
In papers 1 and 3, I found that knowledge of the US Public Health Service Study of 
Untreated Syphilis in the Negro Male, distrust of healthcare professionals, and past experiences 
of discrimination in a healthcare setting were not associated with willingness to participate in a 
clinical trial or enrollment in the University of Michigan Clinical Studies registry; however, this 
does not mean that racism is no longer a salient issue for minorities.  To the contrary, any 
discussion about African Americans and research is incomplete without acknowledging the role 
that institutional racism has played and continues to play in shaping attitudes about medical 
research.  For example, slaves were forced to participate in medical research and demonstration 
projects.1 The poor and enslaved were used to fill hospital beds to help doctors practice and 
perfect their craft.2  Segregated hospitals may have impacted African Americans’ attitudes about 
clinical trials over time.3  In many cases, they received poor care at segregated hospitals which 
may have affected the trust that African American patients had in the scientific establishment and 
to some degree, non-African American physicians.  In 2013, extreme acts of racism may be less 
obvious and frequent, yet nuanced expressions of racism may still impact minority attitudes 
about clinical trials.  Future work will benefit from more specific measures of racism and 
discrimination than were used on my Body & Soul Clinical Trials Project surveys (e.g., the 
Everyday Discrimination Scale).4  
Institutional racism also impacted medical school admissions and in turn, the number of 




(AMA), the largest physician group in the United States, apologized to African American 
doctors for a history of racial discrimination. “The effects of this history have been far reaching 
for the medical profession and, in particular, the legacy of segregation, bias, and exclusion 
continues to adversely affect African American physicians and the patients they serve.”5 
Currently, African Americans comprise 4% of all U.S. physicians and surgeons despite being 
13% of the population.6 The lack of diversity within the medical field may affect the desire of 
African American patients and communities of color to participate in research.  Further work is 
needed to examine of the impact of minority physicians on minority patient interest and 
participation in clinical trials.   
Residential Segregation   
Residential segregation refers to the “physical separation of the races in residential 
context”7 and is often measured by the U.S. Census index of dissimilarity scale.8 With regard to 
African Americans’ ability to access quality medical and healthcare organizations for which 
clinical trials are offered, residential segregation impacts where hospitals are located and the 
number of hospitals in a given area. Healthcare facilities are more likely to close in poor and 
minority communities than in other areas;9-10 thus, it is possible that hospitals in underserved 
areas operate on smaller budgets than large health systems and have less of a research 
infrastructure. Limited resources to conduct medical research may affect a community hospital’s 
ability to open clinical trials and subsequently impacts the number of clinical trials available in 
minority areas.  A future study could utilize geographic information system (GIS) software to 







To increase the full participation of minorities in medical research, it is important that the 
clinical trials offered at a healthcare organization match the patient population. For example, if 
an organization sees 75% African American patients, then having several clinical trials for skin 
cancer may be problematic because skin cancer is predominantly diagnosed in white patients.  
Alternatively, opening clinical trials for triple negative breast cancer or prostate cancer is more 
appropriate, as these cancers are common among African Americans.11  It should be noted that 
healthcare organizations have autonomy in deciding which clinical trials will be conducted at 
their site.  The decision about which clinical trials are opened is influenced by investigator 
interest, buy-in from the research staff, administrative burden, and the cost of carrying out the 
trial (e.g., reimbursement rates by funders).  These decisions significantly impact the number of 
clinical trials for which a patient is eligible, as well as a patient’s proximity to relevant clinical 
trials for his or her disease; which has implications for travel burden.  
Several factors affect an organization’s ability to conduct research.  Most notably, an 
adequate research infrastructure and efficient institutional review board are critical.  The issues 
of infrastructure are especially challenging for hospitals in underserved areas, thus the NIH 
National Center for Research Resources has created a Research Infrastructure division aimed to 
enhance the competitiveness of investigators in underserved states and institutions.12 Ultimately, 
minorities may be systematically excluded from clinical trials because the organizations in which 
they get their care do not have adequate resources to conduct clinical and health research.  More 
structural interventions are needed to improve how clinical trials are conducted at health 




supports (e.g., data analysts and research nurses), use of informatics to identify eligible patients, 
and monitoring of high and low accrual studies to determine best practices.13  
Healthcare Provider Attitudes 
In paper 2, the two leading reasons that physicians did not offer a clinical trial to a cancer 
patient were; 1) preference for standard treatment; and 2) concerns about the patient’s co-
morbidities/frailty.  It is possible that physician preference/bias is a driver in the minority 
disparity in clinical trials.  It should be noted that both primary care physicians and medical 
oncologists have concerns about enrolling patients onto trials if they feel that the patient does not 
understand what is involved.14 Rigid protocol designs, limited time to discuss clinical trials, and 
limited confidence in their ability to explain clinical trials in lay terms are additional 
limitations.15  For referring primary care physicians, fear of losing a patient and revenue is a 
commonly cited reason for not referring patients to clinical trials conducted at other medical 
centers.16  Conflict of duality (the internal conflict that arises from caring for patients, but also 
conducting research) is another challenge for providers.  Clinical trials are ideally designed to 
benefit the individual and society; however, in many cases the benefit is balanced more 
favorably for society and future patients.  Although physicians generally agree about the value of 
what can be learned in clinical trials, barriers include paperwork requirements, time constraints, 
and concerns for patient welfare.17  Further work is needed to understand what 
resources/supports providers may need to fully participate in clinical trial research.   
Patient-Provider Communication 
A better understanding is needed of patient-provider communication in the context of 
clinical trials; currently it is not clear whether all eligible patients are being offered clinical trials.  




patients, and family/companions video recorded at two cancer centers and found that clinical 
trials were explicitly offered in 20% of the interactions; however, when offers were made and 
patients perceived they were offered a trial, 75% of patients consented.18  The overall conclusion 
was that a large percentage of patients are not offered trials; however, when they are offered 
trials, most patients will enroll. Factors still to be explored include how clinical trials are offered 
and explained to patients.  
Given the literature on provider bias, it is possible that minority patients are 
underrepresented in clinical trials in part because healthcare providers are not offering this option 
routinely.19-21 A recent study by Eggly et al. entitled, “A disparity of words: racial differences in 
oncologist-patient communication about clinical trials,” found that compared to visits with white 
patients, clinical visits with African American patients were shorter and included fewer mentions 
and less discussion of clinical trials.22  Clinical trial discussions with African American patients 
focused more on voluntary participation and less on the purpose and risks of the clinical trial 
being offered.  More studies are needed to assess whether providers are offering clinical trials at 
the same rate across racial and ethnic groups, and which members of the study team (doctors, 
nurses, and study coordinators) are most effective at discussing clinical trials with patients.   
Decision-Making for Clinical Trials 
Future work should examine whom, if anyone helps minority patients decide to join a 
clinical trial.  It will be informative for researchers to know what role social networks may play 
in this process and which entity has the biggest influence on the decision: physicians, family, 
friends, pastors, social workers, and/or other patients.   In particular, the impact of the physician 
is of interest, as doctors differ in their comfort level and experience with clinical research.  In 




African American cancer patients report more physical and financial challenges, as well as lower 
social support than white patients.23-25  Church involvement and relationships within the faith 
community have been shown to be important to African Americans;26 however, less is known 
about how, if at all, these social relationships might affect their decision to participant in clinical 
trials and whether faith-based interventions are effective channels for delivering clinical trial 
education programs.    
 Participation of African American Men in Clinical Trials  
It has been historically true that men, and especially white men, were better represented 
in clinical trials than women.27  However, in paper 1, I found that women were more willing to 
participate in a clinical trial than men.  In paper 2, sex was not associated with enrollment in a 
cancer clinical trial nor was sex associated with enrollment in the University of Michigan 
Clinical Studies registry in paper 3. It is possible that these conflicting findings are due to the 
characteristics of each sample (i.e., church members compared to cancer patients).  To further 
explore this issue, I examined sex-specific differences by race in the NCCCP data set (see 
appendix) and found that African American men did not differ from white men in cancer clinical 
trial enrollment, refusal, desire to participate in research, or physical/medical conditions that 
would make them ineligible for a clinical trial; however, Asian men had lower odds of 
enrollment.  While it is unclear why Asian men are less represented in clinical trials, it is 
possible that language barriers, less awareness about clinical trials, or cultural differences are 
contributing factors.28  Additionally, there were no racial/ethnic differences among men in a MD 
declining to offer a clinical trial to an eligible patient.  
Given the inconsistencies in reporting of results from clinical trials by race and ethnicity, 




difficult to find;29-30 however, a few studies exist that focus primarily on African American 
men.31  For example, African American men were well represented in the Selenium and Vitamin 
E Cancer Prevention Trial (SELECT) for prostate cancer; comprising 15% of the sample.32  In a 
study by Byrd et al entitled, “Recruiting Intergenerational African American Males for 
Biomedical Research Studies: A major research challenge,” researchers found that African 
American males across all ages are willing to participate in various types of research studies; 
their participation is influenced by education level; and their decision to participate in research 
studies is often motivated by civic duty, monetary compensation, and whether they or a relative 
has had the disease of interest.33   
Other studies have shown differences in clinical trial participation by male sex, but 
without regard to race/ethnicity.  Cooke et al found that men were less likely to be enrolled in a 
lung injury clinical trial due to co-morbidity34 while another study of patients with lung and 
colorectal cancers found that females had higher odds of enrollment than males (OR=1.36; CI: 
1.1-1.68).35  Future studies should examine gender willingness to participate in clinical trials, 
actual enrollment, and long-term retention by race/ethnicity.  Future work should also assess 
whether there are racial/ethnic differences in men’s response to various recruitment methods36 
and whether men’s experiences once enrolled in a clinical trial may differ from women’s (e.g., 
adverse events and satisfaction with the research team). 
Health Literacy and Public Awareness 
It is estimated that only 12% of American adults have proficient health literacy skills.37   
Health literacy is defined as the ability to understand health information and to use that 
information to make good decisions about health and medical care.38  Health literacy also 




trials are sometimes explained in terms of risk or statistics (e.g., the chance of experiencing 
nausea is about 10%). It is possible that a patient’s health literacy level influences his or her 
willingness to enroll in a study.  Similarly, low literacy has been associated with poor health 
outcomes (e.g., more hospitalizations) and less frequent use of preventive services.40  Future 
work should evaluate the use of plain language (sometimes referred to as plain English) and 
grade level readability on informed consent documents and patient education materials for 
clinical trials.  Per Robert Eagleson’s definition,  
“Plain English is clear, straightforward expression, using only as many words as are 
necessary. It is language that avoids obscurity, inflated vocabulary and convoluted 
sentence construction. …  Writers of plain English let their audience concentrate on the 
message instead of being distracted by complicated language. They make sure that their 
audience understands the message easily.”41 
 
Finally, the impact of the media in shaping public attitudes about clinical trial warrants 
exploration.  National campaigns promoting clinical trials have been limited42-43 and in the last 
10 years, two important books have been written about African Americans and medical research; 
further exposing past racism and scientific missteps.  These books include Medical Apartheid: 
the Dark History of Medical Experimentation on Black Americans From Colonial Times to the 
Present and The Immortal Life of Henrietta Lacks.1, 44 Movies about medical research have also 
been made such as Miss Evers' Boys about the US Public Health Service Study of Untreated 
Syphilis in the Negro Male and Hole in the Head: A Life Revealed, a documentary about Vertus 
Hardiman, who at the age of five became the victim of a medical experiment that left him with a 
physical deformity.45 It is not known how, if at all, such books, movies, or national news stories 
have impacted minority participation in clinical trials.  Cross-sectional surveys or qualitative 
interviews with healthy volunteers and patients with health conditions may elucidate the 




Application of Theory 
More theory-based approaches may help researchers better identify psychological and 
behavioral predictors of enrollment in a clinical trial.  While my grand conceptual model in the 
introduction focused on the Theory of Planned Behavior combined with constructs from an 
ecological framework, using an Integrated Behavioral Model may enhance future research.  Like 
the Theory of Reasoned Action and Theory of Planned Behavior, the Integrated Behavioral 
Model suggests that the most important determinant of behavior is intention to perform the 
behavior; thus, if a person is not motivated to change or implement a behavior, it is unlikely to 
occur.  That is, even with strong behavioral intention, a person still needs to possess the 
knowledge and skills to do the behavior (e.g., knowledge of clinical trials and how to enroll), 
minimal environmental constraints that make the task difficult (e.g., transportation), and salience 
toward the topic (e.g., belief that a clinical trial is important to the person, their community, or 
someone they care about).46   
Conclusion 
In closing, I entitled this dissertation “Rethinking Minority Participation in Clinical 
Trials:  More than Mistrust" to challenge how researchers think about this issue. It is quite 
possible that the problems to be fixed with regard to minority participation in clinical trials are 
not the attitudes or beliefs of patients, but rather the current practices of investigators.  
Improvements in how the research community engages minority patients, designs protocols, and 
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Select Post-Test Items on Enrollment in the U-M Clinical Studies Registry. 
 
FIQ17. In your opinion, what percentage of your friends and family members would 
participate in a clinical trial? Check one.  
 
 None   Some   Most  All   Can’t say 
 
 
FIQ18. If you decided to participate in a clinical trial, how much would your family and 
friends support that decision? Check one. 
 
 Not at all   A little   Some  A lot  Can’t say 
 
 
FIQ19.  Scientists are interested in the role of genetics in human diseases. Learning how 
people's genes interact with their behaviors and environment to cause illness is the goal 
of many research studies. This kind of research is seen as helpful to better 
understanding and treatment of certain diseases. 
On a scale of 1 to 5, with 1 being “not at all willing” and 5 being “very willing,” how willing would 
you be to participate in a clinical trial that asked you to give a blood or saliva sample to better 
understand the impact of genetics on a health condition?” Circle one.  









Very willing  
 1  2   3   4   5 
 
 
FIQ20. Do you have health insurance?   
 
    Yes     No (skip to #20)    Don’t Know  
 
FIQ20a. If you have insurance, what kind do you have? Check all that apply. 
 
 Private (e.g. Blue Cross Blue Shield, United, HAP) 
 Medicaid  
 Medicare  
 Medicare supplement 
 County health plan (e.g. Washtenaw County Health Plan) 






FIQ21. In general, would you say your health is: 
 
 Poor        Fair   Good      Very good   Excellent   
 
 
FIQ22. Where do you regularly receive your healthcare?  Check all that apply.   
 Private doctor  
 Hospital or health system  
 Neighborhood clinic  
 Health department  
 Clinical trials  
 Other (Specify)________________ 






Research suggests that having a health condition(s) may influence a person’s decision 
to participate in a clinical trial.  The following question will help us understand the 
relationship, if any, between health status and clinical trial participation.  
 
FIQ23. Do you have any of the following health conditions? Check all that apply.  
 
  Myocardial infarction (history of heart attack) 
  Congestive heart failure (heart can't pump enough blood throughout the body) 
  Peripheral disease (narrowing of the blood vessels outside of your heart)  
  Cerebrovascular disease (stroke) 
  Chronic pulmonary disease aka COPD (e.g. chronic bronchitis or    emphysema) 
  Connective tissue disease (cartilage and fat are examples of connective tissue) 
  Peptic ulcer disease	  (sores in lining of your stomach or duodenum, the first part of small  
intestine) 
  Mild liver disease (without hypertension, includes chronic hepatitis)  
  Moderate or severe liver disease 
  Diabetes without end-organ damage (excludes diet-controlled alone)  
  Diabetes with end-organ damage (retinopathy, neuropathy, nephropathy, or brittle diabetes)  
  Hemiplegia, aka paralysis (the loss of muscle function in part of your body) 
  Moderate or severe renal disease (kidney disease) 
  [Cancer] tumor without metastasis (spread of cancer).  Exclude if more than 5 years from 
diagnosis 
  Metastatic solid tumor (cancer that has spread to other places) 
  Leukemia (acute or chronic) - cancer of the white blood cells 
  Lymphoma (cancer of a part of the immune system called the lymphatic system) 
  Autoimmune disease (e.g. arthritis, lupus, multiple sclerosis) 
  Overweight/Obesity 
  Chronic pain 








Table 14: Univariate post-test predictors of enrollment in the U-M Clinical Studies 
Registry. Logistic regression.  
 
 
*Statistically significant, p < .05  
 Odds Ratio 95% CI P-value 
In your opinion, what percentage of 
your friends and family members 
would participate in a clinical trial 
.95 .56 - 162 .86 
If you decided to participate in a 
clinical trial, how much would your 
family and friends support that 
decision 
1.09 .75 – 1.6 .65 
Willingness to participate in a 
clinical trial that asked you to give 
blood or a saliva sample to better 
understand the impact of genetics 
on a health condition* 
(mean score 3.9) 
1.57 1.15 – 2.14 .004 
Do you have health insurance 1.27 .44 – 3.66 .67 
Self-rated health .75 .54 – 1.05 .1 
# Medical/physical conditions 
(index) 





Table 15: Post-test willingness to participate in genetics research on enrollment in the U-M 
Clinical Studies Registry, controlling for baseline demographics. Multivariate logistic 
regression.  
 Odds Ratio 95% CI P-value 
Willingness to participate in 
a clinical trial that asked you 
to give blood or a saliva 
sample to better understand 
the impact of genetics on a 
health condition* 
1.57 1.13 – 2.19 .01 
Sex 1.55 0.75 – 3.2 .24 
Age 1.02 1.0 – 1.04 .24 
Education 0.77 0.41 – 1.45 .42 
Work Status 0.75 0.52 – 1.1 .14 
Household income 1.29 0.83 – 2.01 .26 
 






Post-Dissertation Defense Analyses 
 
Paper 1: Post-hoc analyses  
 
Table 16: Multivariate Linear Regression. Willingness to participate in a clinical trial by 
demographic and aggregate scale correlates, with barriers broken into personal and structural. 









Sex .30 .144 
Education  .29 .132 
Work Status .165 .133 
Household Income -.15 .265 
Age -.006 .341 
Global Trust Scale .149 .422 
Patient-Provider 
Communication Scale -.102 .535 
Personal Benefit Scale* 1.19 <.001 
Global Benefits Scale* 1.12 <.001 
Structural Barriers Scale .038 .821 
Personal Barriers* -.484 .001 
 








Table 17: Multivariate Linear Regression. Willingness to participate in a clinical trial by 
demographic and aggregate scale correlates; with barriers broken into personal and structural, 
and I have heard of a clinical trial. 





Sex .28 .145 
Personal benefit scale* .55 .002 
Global benefit scale* .64 <.001 
Structural barriers scale -.26 .119 
Personal barriers* -.312 .02 
Heard of a clinical trial .79  <.001 
I have experienced 
discrimination in a healthcare 
setting -.029 .685 
Amount of payment or incentive 
for participating in a clinical 
trial* .19 .04 
Healthcare providers involve you 
in decisions about your health 
care* .336 .008 
Healthcare providers explain 
things in a way that you can 
understand -.227 .14 
Knowledge of the US Public 
Health Service Study of 
Untreated Syphilis in the Negro 
Male -.093 .619 
Distrust of healthcare 
professionals -.077 .354 
Trust in organization conduction 
the trial* 1.34 <.001 
 


























Models run with transformed data for willingness to participate in a clinical trial. 
Table 18: Multivariate Linear Regression. Transformed willingness to participate in a clinical 
trial item by demographic and aggregate scale correlates, with barriers broken into personal and 
structural. 









Sex .34 .198 
Education  .47 .06 
Work Status .17 .225 
Household Income -.17 .344 
Age -.01 .571 
Global Trust Scale .25 .311 
Patient-Provider 
Communication Scale -.06 .79 
Personal Benefit Scale* 1.21 <.001 
Global Benefits Scale* 1.42 <.001 
Structural Barriers Scale -.101 .649 
Personal Barriers -.66 <.001 
 





Table 19. Multivariate Linear Regression. Transformed willingness to participate in a clinical 




Sex .38 .14 
Personal benefit scale* .55 .02 
Global benefit scale* .9 <.001 
Structural barriers scale -.44 .05 
Personal barriers* -.43 .01 
Heard of a clinical trial* 1.26  <.001 
I have experienced 
discrimination in a healthcare 
setting -.05 .59 
Amount of payment or incentive 
for participating in a clinical 
trial* .18 .14 
Healthcare providers involve you 
in decisions about your health 
care* .45 .008 
Healthcare providers explain 
things in a way that you can 
understand -.2 .328 
Knowledge of the US Public 
Health Service Study of 
Untreated Syphilis in the Negro 
Male -.1 .694 
Distrust of healthcare 
professionals -.06 .574 
Trust in organization conduction 
the trial* 1.43 <.001 
 











Paper 2: Post-hoc analyses  
Table 20: Reasons given for patients was eligible but declined clinical trial (Q. 14)  
Item n 
Cultural/religious issues 0 
Did not keep appointment 11 
Family member influenced against trial participation 26 
Financial concerns/indirect costs 28 
Insurance company refused to pay for additional testing 2 
Insurance company denied coverage 18 
Lack of awareness/education about clinical trials 8 
Language barrier/lack of access to interpreter 2 
Mistrust of research 12 
No desire to participate in research  364 
No insurance coverage 5 
Palliative care/hospice 7 
Patient declined to be retested per protocol 9 
Patient referred to another trial 0 
Perceived side effects/toxicities too great 84 
Preference for standard treatment 371 
Preferred no treatment 30 
Refused to have re-biopsy or further tissue collection 7 
Second opinion/transfer of care 30 
Social issues (housing/childcare) 12 






Table 21: Men only by race/ethnicity. Enrollment in a cancer clinical trial. (n=1367) 






Black men .74 .49 – 1.11 .14 
Hispanic men .48 .22 - 1.07 .07 
Asian men* .13 .03 - 56 .006 
Other men z z z 
 







Table 22: Men only by race/ethnicity. Patient eligible but declined clinical trial.  (n=1367) 






Black men 1.04 .7 – 1.58 .83 
Hispanic men 1.25 .65 – 2.42 .5 
Asian men .6 .25 – 1.42 .25 







Table 23: Men only by race/ethnicity. No desire to participate in research as reason given 
for declining a clinical trial. (n=1367) 






Black men .79 .41 – 1.51 .48 
Hispanic men 1.44 .6 – 3.46 .41 
Asian men .48 .15 – 2.01 .25 










Table 24:  Men only by race/ethnicity. Physical/medical conditions.  (n=1367) 






Black men .9 .63 – 1.3 .58 
Hispanic men .76 .4 – 1.44 .4 
Asian men .75 .39 – 1.347 .41 
Other men 2.11 .7 – 6.3 .18 
 






Table 25: Men only by race/ethnicity. MD declined to offer clinical trial participation to an 
eligible patient.  (n=1367) 






Black men 1.05 .6 – 1.8 .87 
Hispanic men 1.32 .58 – 3.04 .51 
Asian men 1.29 .56 – 2.9 .54 



























Paper 3: Post-hoc analyses 
 
 
Table 26: Enrollment in the registry by baseline aggregate scales. *Structural and personal 
barriers separated. Multivariate logistic regression (n = 600).  
 Odds Ratio 95% CI P-value 
Treatment condition 
(control, ref)* 
2.72 1.48 – 5.02 .001 
Patient-Provider 
Communication 
.99 .6 – 1.63 .96 
Personal Benefit .98 .59 – 1.66 .95 
Global Benefit 1.48 .78 – 2.78 .228 
Personal Barriers .75 .48 – 1.15 .181 
Structural Barriers 1.02 .62 – 1.68 .94 
Global Trust 1.16 .66 – 2.04 .611 
 







Table 27: Enrollment in the registry by individual baseline survey items, plus heard of a 
clinical trial (n=575). Multivariate logistic regression.  
 Odds Ratio 95% CI P-value 
 
Treatment condition (control, ref)* 
 
2.92 1.47 – 5.71 .002 
Heard of a clinical trial 2.34 .88 – 5.65 .09 
Willingness to participate in a 
clinical trial in the future 
1.15 .98 – 1.35 .08 
Inconvenience or “hassle” 
associated with a clinical trial* 
.71 .53 – 0.94 .02 
Participating in research is my 
responsibility to the black 
community 
1.01 .74 – 1.37 .96 
I have experienced discrimination 
in a healthcare setting 
.78 .64– 1.0 .05 
Knowledge of the US Public Health 
Service Study of Untreated Syphilis 
in the Negro Male 
1.52 .72 – 3.23 .27 
 
*Significantly significant, P < .05 
 
